

JP2004_018717.trn

Dialing COMPUERVE at 007067040088

OK

CONNECT 48000

Connecting through CompuServe

0018TEW

Host Name: STNT

Connected to 0006 CAA_0

Welcome to STN International! Enter x:x
LOGINID:TKYBAJ74
PASSWORD:
TERMINAL (ENTER 1, 2, 3, EUC, SJIS, OR 7):2

***** Welcome to STN International *****

Item	Date	Headline
NEWS 1		STN, CAS FILES Workshop Schedule in Japan
NEWS 2	Oct 26	KOREAPAT now available on STN
NEWS 3	Nov 19	Current-awareness alerts, saved answer sets, and current search transcripts to be affected by CERAB, COMPUAB, ELCOM, and SOLIDSTATE reloads
NEWS 4	Nov 22	November 22, 2004 LISA new on STN
NEWS 5	Dec 1	PHAR reloaded with additional data
NEWS 6	Dec 15	12 databases to be removed from STN on 31, Dec., 2004
NEWS 7	Dec 17	MEDLINE update schedule for December 2004
NEWS 8	Dec 20	ELCOM reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 9	Dec 20	COMPUAB reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 10	Dec 20	SOLIDSTATE reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 11	Dec 20	CERAB reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 12	Dec 20	Thres new fields added to IFIPAT/IFIUDB/IFICDB
NEWS 13	Dec 27	EPFULL:New patent full text database to be available on STN
NEWS 14	Dec 31	CAPLUS - PATENT COVERAGE EXPANDED
NEWS 15	Jan 1	No connect-hour charges in EPFULL during January and February 2005
NEWS 16	Jan 5	Urgent announcement to STN customers accessing via phone line WorldCom access points were changed
NEWS 17	Jan 12	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS HOURS		STN operating Hours
NEWS WORLDCOM		STN High Speed Access via Worldcom
NEWS INTER		INTERNET ACCESS to STNT(STN-Tokyo)

Page 1

JP2004_018717.trn


ring/chain nodes :
3 14 15
chain bonds :
1-2 1-5 2-3 2-4 15-16 15-17
ring/chain bonds :
3-14 14-15
ring bonds :
5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 1-5 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17
isolated ring systems :
containing 5 :

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS

L1 STRUCTURE UPLOADED

=> Uploading A:\018717A.str



chain nodes :
1 2 4 16 17 20 21
ring nodes :
5 6 7 8 9 10
ring/chain nodes :
3 14 15
chain bonds :
1-2 1-5 2-3 2-4 15-16 15-17 16-20 20-21
ring/chain bonds :
3-14 14-15
ring bonds :
5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 1-5 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17
16-20 20-21
isolated ring systems :
containing 5 :

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS 20:CLASS 21:Atom

JP2004_018717.trn

NEWS EXPRESS STN Express 7.0 with Discover!
(Windows) Now available!
NEWS WWW STN Tokyo World Wide Web Site

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:44:23 ON 08 FEB 2005

=> FILE REG COS=4PRD
COST IN JAPANESE YEN

SINCE FILE	TOTAL
ENTRY	SESSION
36	36

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:44:34 ON 08 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)
CHARGED TO COST=4PRD

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-7
DICTIONARY FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-7


TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> Uploading A:\018717.str



chain nodes :
1 2 4 17
ring nodes :
5 6 7 8 9 10 16

Page 2

JP2004_018717.trn

Generic attributes :
16:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 21: Limited
N,N1

L2 STRUCTURE UPLOADED

=> S L1 AND L2 SAM
SAMPLE SEARCH INITIATED 13:45:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2819 TO ITERATE


35.5% PROCESSED 1000 ITERATIONS 9 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 53196 TO 59564
PROJECTED ANSWERS: 205 TO 809

L3 9 SEA SSS SAM L1 AND L2

=> D SCAN

L3 9 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-(3-[[[2,3-dichlorophenyl]amino]carbonyl]
(1-methylethyl)amino]-1-oxopropyl)- (9CI)
MF C25 H28 Cl2 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> S L1 AND L2 FUL
FULL SEARCH INITIATED 13:45:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 56823 TO ITERATE

100.0% PROCESSED 56823 ITERATIONS 349 ANSWERS
SEARCH TIME: 00.00.04

W = -N-

=> Uploading A:\018717B.str




chain nodes :
1 2 3 4 14 15 17
ring nodes :
5 6 7 8 9 10 16
chain bonds :
1-2 1-5 2-3 2-4 3-14 14-15 15-16 15-17
ring bonds :
5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 1-5 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17
isolated ring systems :
containing 5 :

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS

L5 STRUCTURE UPLOADED

=> Uploading A:\018717C.str



chain nodes :
1 2 3 4 14 15 16 17 20 21
ring nodes :
5 6 7 8 9 10
chain bonds :
1-2 1-5 2-3 2-4 3-14 14-15 15-16 15-17 16-20 20-21
ring bonds :
5-6 5-10 6-7 7-8 8-9 9-10

Page 5

JP2004_018717.trn


ring bonds :
5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 1-5 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17
isolated ring systems :
containing 5 :

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS

L8 STRUCTURE UPLOADED

=> Uploading A:\018717CC.str



chain nodes :
1 2 3 4 14 15 16 17 20 21
ring nodes :
5 6 7 8 9 10
chain bonds :
1-2 1-5 2-3 2-4 3-14 14-15 15-16 15-17 16-20 20-21
ring bonds :
5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 1-5 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17
16-20 20-21
isolated ring systems :
containing 5 :

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS 20:CLASS 21:Atom
Generic attributes :
16:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 21: Limited
N,N1

exact/norm bonds :
1-2 1-5 2-3 2-4 3-14 5-6 5-10 6-7 7-8 8-9 9-10 14-15 15-16 15-17
16-20 20-21
isolated ring systems :
containing 5 :

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 14:CLASS 15:CLASS 16:Atom 17:CLASS 20:CLASS 21:Atom
Generic attributes :
16:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 21: Limited
N,N1

L6 STRUCTURE UPLOADED


=> S L5 AND L6 SAM
SAMPLE SEARCH INITIATED 13:47:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 47198 TO ITERATE

2.14 PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 931002 TO 956918
PROJECTED ANSWERS: 0 TO 0

L7 0 SEA SSS SAM L5 AND L6

=> Uploading A:\018717BB.str



chain nodes :
1 2 3 4 14 15 17
ring nodes :
5 6 7 8 9 10 16
chain bonds :
1-2 1-5 2-3 2-4 3-14 14-15 15-16 15-17

Page 6

JP2004_018717.trn

L9 STRUCTURE UPLOADED

=> S L8 AND L9 SAM
SAMPLE SEARCH INITIATED 13:50:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 165 TO ITERATE

100.0% PROCESSED 165 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2530 TO 4070
PROJECTED ANSWERS: 0 TO 0


L10 0 SEA SSS SAM L8 AND L9

=> S L8 AND L9 FUL
FULL SEARCH INITIATED 13:50:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3239 TO ITERATE

100.0% PROCESSED 3239 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L11 0 SEA SSS FUL L8 AND L9

=> Uploading A:\018717D.str




chain nodes :
1 2 3 13 14 16
ring nodes :
4 5 6 7 8 9 15
chain bonds :
1-2 1-4 2-3 2-13 13-14 14-15 14-16
ring bonds :
4-5 4-9 5-6 6-7 7-8 8-9
exact/norm bonds :
1-2 1-4 2-3 2-13 4-5 4-9 5-6 6-7 7-8 8-9 13-14 14-15 14-16
isolated ring systems :
containing 4 :

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
13:CLASS 14:CLASS 15:Atom 16:CLASS

L12 STRUCTURE UPLOADED

=> Uploading A:\018717E.str



chain nodes :
1 2 3 13 14 15 16 19 20
ring nodes :
4 5 6 7 8 9
chain bonds :
1-2 1-4 2-3 2-13 13-14 14-15 14-16 15-19 19-20
ring bonds :
4-5 4-9 5-6 6-7 7-8 8-9
exact/norm bonds :
1-2 1-4 2-3 2-13 4-5 4-9 5-6 6-7 7-8 8-9 13-14 14-15 14-16 15-19 19-20
isolated ring systems :
containing 4 :

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
13:CLASS 14:CLASS 15:Atom 16:CLASS 19:CLASS 20:Atom
Generic attributes :
15:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 20: Limited
N,N1

L13 STRUCTURE UPLOADED

=> S L12 AND L13 SAM
SAMPLE SEARCH INITIATED 13:52:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1798 TO ITERATE

55.6% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

Page 9

JP2004_018717.trn

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 6 Feb 2005 (20050206/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L15
L18 9 L15
=> S L18 AND P/DT
4628444 P/DT
L19 8 L18 AND P/DT

=> D BIB ABS HITSTR 1-8

L19 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:964811 CAPLUS
DN 141:395810
TI Preparation of heterocyclic dipeptides as hepatitis C inhibitors
IN Bailey, Murray D.; Llinas-Brunet, Montse
PA Boehringer Ingelheim International GmbH, Germany
SO U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004224900	A1	20041111	US 2004-791318	20040302
WO 2004101602	A2	20041125	WO 2004-CA319	20040302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RD, RU, RO, RS, SC, SE, SG, SK, SL, SY, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LO, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2003-452187P P 20030305
OS MARPAT 141:395810
GI

BATCH **COMPLETE**
PROJECTED ITERATIONS: 33417 TO 38503
PROJECTED ANSWERS: 0 TO 0

L14 0 SEA SSS SAM L12 AND L13

=> S L12 AND L13 FUL
FULL SEARCH INITIATED 13:52:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 35773 TO ITERATE

100.0% PROCESSED 35773 ITERATIONS
SEARCH TIME: 00.00.02

31 ANSWERS

L15 31 SEA SSS FUL L12 AND L13

=> SAV TEMP L4 RD018717/A

=> FILE CAOLD
COST IN JAPANESE YEN

SINCE FILE	TOTAL
ENTRY	SESSION
63220	63256

FULL ESTIMATED COST

FILE 'CAOLD' ENTERED AT 13:53:00 ON 08 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
CHARGED TO COST=4PRD

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> S L4
L16 0 L4

=> S L15
L17 0 L15

=> FILE CAPLUS
COST IN JAPANESE YEN

SINCE FILE	TOTAL
ENTRY	SESSION
65	63321


FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:53:14 ON 08 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
CHARGED TO COST=4PRD

Copyright of the articles to which records in this database refer is

Page 10

JP2004_018717.trn




AB Peptides I [B is (un)substituted alkyl, cycloalkyl, Ph or heteroaryl; Y is H or alkyl; R3 is alkyl or (un)substituted cycloalkyl; R2 is (un)substituted alkyl or cycloalkyl, an amino or acylamino group; R24 is alkoxy, mono- or dialkylamino; R1 is alkyl or alkenyl; RC is OH or NHSO2RS, where RS is (cyclo)alkyl, alkylcycloalkyl, Ph, naphthyl or pyridinyl which are optionally substituted] or their racemates, diastereoisomers, optical isomers or pharmaceutically-acceptable salts were prepared as inhibitors of the hepatitis C virus (HCV) NS3 protease. Thus, I (B = R3 = t-Bu, Y = H, R2 = NHAc, R24 = OMe, R1 = CH:CH2, RC = OH) was prepared and shown to have IC50 < 0.1 µM in the NS3-NS4A protease assay and EC50 ≤ 0.5 µM in the cell-based HCV RNA replication assay.

IT 784178-97-8P 784179-01-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of heterocyclic dipeptides as hepatitis C inhibitors)


RN 784178-97-8 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[[[(2S,4R)-4-[[[2-(2-(acetylamino)-4-thiazolyl]-7-methoxy-4-quinolinyl]oxy]-1-[(2S)-3,3-dimethyl-1-oxo-2-oxo-2-(phenylamino)ethyl]butyl]-2-pyrrolidinyl]carbonyl]amino]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 784179-01-7 CAPLUS
 CN Cyclopropanecarboxylic acid, 1-[[[(2S,4R)-4-[[[7-(dimethylamino)-2-[2-[(3,3-dimethyl-1-oxobutyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-1-[(2S)-3,3-dimethyl-1-oxo-2-[2-oxo-2-(phenylamino)ethyl]butyl]-2-pyrrolidinyl]carbonyl]amino]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L19 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:819908 CAPLUS
 DN 141:307555
 TI 1-(1-Substituted-4-piperidinylmethyl)piperidine derivatives as 5-HT4 receptor agonists, pharmaceutical compositions containing them, and their use
 IN Kato, Shiro; Yamazaki, Hiroshi; Hirokawa, Yoshimi; Suga, Yoko; Yoshida, Naoyuki; Morikage, Yukiko; Morikage, Kazuo; Oku, Seiko
 PA Dainippon Pharmaceutical Co., Ltd., Japan
 SO Japan Kokai Tokkyo Koho, 37 pp.
 CODEN: JKKXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

Page 13



CM 2
 CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



L19 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STM
 AN 2004:566599 CAPLUS
 DN 141:123613
 TI Preparation of piperidinyl thiazole carboxamide derivatives for altering vascular tone
 IN Knox, Peter; Pappa, Helen; Lam, Winnie
 PA Metris Therapeutics Limited, UK
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004058751	A1	20040715	WO 2003-GB5654	20031224
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OH, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BM, GB, GM, KE, LS, MM, MC, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI GB 2002-30162	A	20021224		
OS MARPAT 141:123613				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. I and II [Q = (substituted)alkyl, (substituted)alkenyl,

PI JP 2004277318
 PRAI JP 2003-69326
 OS MARPAT 141:307555
 GI

A2 20041007
 20030314

JP 2003-69326

20030314



AB The derivs. are represented by I [Ar = Q, Q1; R1 = halo; R2 = H, lower alkyl; R3 = H, lower alkyl, lower alkanoyl; R4 = H, lower alkyl; R5, R6 = H, lower alkyl; h = 1, 2, 3; X = lower alkenyl, cycloalkenyl, lower alkynyl, cycloalkenyl-lower alkyl, CH:CHA; A = halo, lower alkoxy, carbonyl, cycloalkyl, (un)substituted Ph, carbamoyl in which N may be substituted with lower alkyl or (un)substituted Ph, lower alkanoyl, lower alkoxy, unsatd. mono or dicyclic heterocyclyl, saturated monocyclic heterocyclyl;

m = 0, 1; if m = 0, then X = lower alkenyl or their physiologically acceptable acid salts. Also claimed are pharmaceutical compns., 5-HT4 receptor agonists, and digestive tract motility promoters or digestive tract function improvers containing I or their salts. Thus, 4-amino-5-chloro-N-[1-[(1-(3-cyclohexene-1-carbonyl)-4-piperidinylmethyl)-4-piperidinyl]-2-methoxybenzamide fumarate, prepared from 4-amino-5-chloro-2-methoxy-N-[1-(4-piperidinylmethyl)-4-piperidinyl]benzamide and 3-cyclohexene-1-carboxylic acid, inhibited binding of GR113808 to a guinea pig 5-HT4 receptor preparation at IC50 8.71 nM, vs. 23.0 nM of cisapride. Pharmaceutical preps. containing I were also given.

IT 768372-01-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1-(1-substituted-4-piperidinylmethyl)piperidine derivs. as 5-HT4 receptor agonists)

RN 768372-01-6 CAPLUS
 CN Benzamide, 4-amino-5-chloro-N-[1-[(1-(2E)-1,4-dioxo-4-(phenylamino)-2-butenyl)-4-piperidinylmethyl]-4-piperidinyl]-2-methoxy-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 768372-00-5
 CMF C29 H36 Cl N5 O4


Double bond geometry as shown.

Page 14

(substituted)cycloalkyl, (substituted)aryl, (substituted)aralkyl, (substituted)alkoxy, (substituted)aryloxy, etc.; A = a single bond or alkylene; X = O or S; Z = O, S, NR3; R1-R3 = H or alkyl; p = 0 or 1; q = 0 or 1; n = 0-10; m = 0-10] that are specific to the EP3 receptor and useful in altering vascular tone, in particular uterine vascular tone (including myometrial and endometrial vascular tone) were prepared. The invention is particularly useful in the treatment of menstrual disorders, cardiovascular conditions and hypertension. For example, compound III was prepared in a multi-step synthesis. The latter showed an EC50 = 5.7 μM in the EP3 receptor binding assay.


IT 721970-55-4P 721970-56-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of piperidinyl thiazole carboxamide derivs. for altering vascular tone)
 RN 721970-55-4 CAPLUS
 CN 2-Butenamide, 4-[4-[4-(4-bromophenyl)-5-methyl-2-thiazolyl]-1-piperidinyl]-N-(4,5-dimethyl-2-nitrophenyl)-4-oxo-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 721970-56-5 CAPLUS
 CN 2-Butenamide, 4-[4-[4-(diethylamino)phenyl]-2-thiazolyl]-1-piperidinyl]-N-(4,5-dimethyl-2-nitrophenyl)-4-oxo-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L19 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STM
 AN 2003:221465 CAPLUS
 DN 138:255249
 TI Preparation of piperazine and homopiperazine compounds useful in the

treatment of thrombosis and to inhibit ADP-mediated platelet aggregation
IN Levy, Daniel E.; Smyth, Mark S.; Scarborough, Robert M.
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 260 pp.
CODEN: PIXXD2

OT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003022214	A2	20030320	WO 2002-US28618	20020906
	WO 2003022214	A3	20040325		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW



RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, SF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003153556

PRAI US 2001-317192P

OS MARPAT 138:255249

GI




AB Piperazine and homopiperazine compds. I, wherein Q is (CH₂)_n; n is 1, 2; m is 0-4; W is N, CR5; X is S, O, NR6; Y is N, CR7; Z is N, CR8; J is CO, CS, CNR9, SO, SO₂; A is O, S, NR10, CO, CH(OH); L is a direct link or a divalent linker; R1 is H, halo, CN, NO₂, N3, alkyl, cycloalkyl, alkene, alkyne; R2 is H, halo, CN, NO₂, N3, alkyl, cycloalkyl, alkene, alkyne, acyl; R3 is alkyl, cycloalkyl, acyl; R4 is H, F, CF₃, CN, N3, NO₂, alkyl, amino, alkylamino, cycloalkyl, heterocycloalkyl, heteroalkyl, fused bicycloalkyl, fused bicycloalkaryl, fused bicycloalkaryl; R5-R8 are independently H, alkyl, cycloalkyl; R9 is H, CN, NO₂, alkyl; R10 is H, alkyl, acyl; are provided having a piperazine or homopiperazine ring which are useful in the treatment of thrombosis. Thus piperazine II was prepared and tested in vitro to inhibit ADP-mediated platelet aggregation (activity ranges are: > 20 μmol; 10-20 μmol; and < 10 μmol).

IT 502648-44-4P 502648-56-8P

Page 17


JP2004_018717.trn



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L19 ANSWER 5 OF 8 CAPLUS - COPYRIGHT 2005 ACS on STM

AN 2000:548723 CAPLUS

DN 133:150561

TI Preparation of imidazolylalkylazacycloalkanes as H3 receptor antagonists
IN Vaccaro, Wayne D.; Wolin, Ronald L.; Solomon, Daniel M.; Aslanian, Robert G.; Piwinski, John J.; Rosenblum, Stuart B.

PA Schering Corporation, USA

SO U.S., 33 pp.

CODEN: USXXAM

OT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6100279	A	20000808	US 1998-185973	19981105
PRAI	US 1997-64958P	P	19971107		

OS MARPAT 133:150561

GI

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of piperazine and homopiperazine compds. useful in treatment of

thrombosis and to inhibit ADP-mediated platelet aggregation)


RN 502648-44-4 CAPLUS

CN 1-Piperazinepropanamide, 4-(6-ethylthieno[2,3-d]pyrimidin-4-yl)-β-oxo-N-phenyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 502648-43-3


CMF C21 H23 N5 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 502648-56-8 CAPLUS

CN 1-Piperazinepropanamide, 4-(6-ethylthieno[2,3-d]pyrimidin-4-yl)-β-oxo-N-3-pyridinyl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 502648-55-7

CMF C20 H22 N6 O2 S

Page 18

JP2004_018717.trn



AB R1Z1Z(CH₂)mZ2(CH₂)pR6 [I; R1 = (un)substituted 1H-imidazol-4-yl; R6 = (un)substituted heterocyclyl or -(hetero)aryl; Z = (un)substituted pyrrolidine-, -piperidine-, or -hexahydroazepine-n,1-diyl; Z1 = (un)substituted alk(en)ylene, -alkynylene; Z2 = O, CO, CONH, SO₂, etc.; m, p = 0-4; n = 2-6 as appropriate] were prepared. Thus, 1-tritylimidazole-4-propanol was oxidized and the product condensed with (MeO)2P(O)CH₂CO₂Me to give Me 4-(1-tritylimidazol-4-yl)-2-butanolate which was condensed with MeNO₂ and the product reductively cyclized to give 4-[2-(1-tritylimidazol-4-yl)ethyl]-2-oxopyrrolidine. The latter was reduced and the product N-acylated by 4-ClC₆H₄SO₂Cl to give, after deprotection, title compound 11.HCl. Data for biol. activity of I were given.


IT 224168-43-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolylalkylazacycloalkanes as H3 receptor antagonists)

RN 224168-43-8 CAPLUS

CN 1-Piperidinepropanamide, N-(3-chlorophenyl)-4-(1H-imidazol-4-ylmethyl)-β-oxo- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STM

AN 1999:325925 CAPLUS

DN 130:338115

TI Preparation of 4-[(azacycloalkyl)alkyl]imidazoles as histamine H3 receptor antagonists

IN Vaccaro, Wayne D.; Wolin, Ronald L.; Solomon, Daniel M.; Aslanian, Robert G.; Piwinski, John J.; Rosenblum, Stuart B.

PA Schering Corporation, USA

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2


OT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI WO 9924421 A1 19990520 WO 1998-US23224 19981105
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CM, CZ, EE, GE, GR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2309609 AA 19990520 CA 1998-2309609 19981105
AU 9912967 A1 19990531 AU 1999-12967 19981105
EP 1028956 A1 20000823 EP 1998-956443 19981105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI, RO
JP 2001522845 T2 20011120 JP 2000-520435 19981105
ZA 9810186 A 19990506 ZA 1998-10186 19981106
PRAI US 1997-965754 A2 19971107
WO 1998-US23224 W 19981105
OS MARPAT 130:338115
AB R1X2(CH2)mY(CH2)pR6 [I; R1 = (un)substituted 4-imidazolyl; R6 = (un)substituted heterocyclyl or -(hetero)aryl; X = (un)substituted alk(en)ylene or alkynylene; Y = O, CO, CO2, SO2, CONH, etc.; Z = pyrrolidine-, piperidine-, or hexamethyleneimine-n,1-diyl; m, p = 0-4] were prepared. Thus, 1-tritylimidazole-4-propionaldehyde was condensed with (MeO)2P(O)CH2CO2Me and the product condensed with MeNO2 to give, after reduction and cyclization and an addnl. reduction step, 1-trityl-4-[2-(3-pyrrolidinyl)ethyl]imidazole which was amidated by 4-ClC6H4SO2Cl to give, after deprotection, R1CH2CH2ZSO2C6H4Cl-4 (R1 = 4-imidazolyl, Z = pyrrolidine-3,1-diyl). Data for biol. activity of I were given.
IT 224168-43-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-[(azacycloalkyl)alkyl]imidazoles as histamine H3 receptor antagonists)
RN 224168-43-8 CAPLUS
CN 1-Piperidinepropanamide, N-(3-chlorophenyl)-4-(1H-imidazol-4-ylmethyl)-β-oxo- (9CI) (CA INDEX NAME)




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1995:995217 CAPLUS
DN 124:117340
TI Preparation of 4-amino-2-piperazinoquinazolines and analogs as α1-adrenergic antagonists
IN Leonardi, Amedeo; Motta, Gianni; Boi, Carlo; Testa, Rodolfo
PA Recordati S.A. Chemical and Pharmaceutical Co., Switz.
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent


Page 21

JP2004_018717.trn



● HCl


RN 173059-43-3 CAPLUS
CN 1-Piperazinepropanamide, 4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-β-oxo-N-phenyl- (9CI) (CA INDEX NAME)



L19 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:169119 CAPLUS
DN 118:169119
TI Preparation of pyrrolidinylcarbonyl(heterocyclyl)piperazines and related compounds as antiasthmatics and respiratory tract antiinflammatories
IN Long, Giorgio; Gandolfi, Carmelo A.; De Cillis, Gianpiero; Di Domenico, Roberto; Rozzi, Antonella; Gallico, Licia
PA Boehringer Mannheim Italia S.p.A., Italy
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9218478	A1	19921029	WO 1992-EP724	19920401
W: AU, BB, BG, BR, CA, CS, FI, EU, JP, KP, KR, LK, MG, MN, NO, PL, RO, RU, SD, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
AU 9214475	A1	19921117	AU 1992-14475	19920401
AU 653393	B2	19940929		
EP 580633	A1	19940202	EP 1992-907564	19920401
EP 580633	B1	19980617		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06506450	T2	19940721	JP 1992-506863	19920401

LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 9525726 A1 19950928 WO 1995-EP1001 19950317
W: AM, AU, BE, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9518948 A1 19951009 AU 1995-18948 19950317
ZA 9502208 A 19951228 ZA 1995-2208 19950317
EP 750614 A1 19970102 EP 1995-911342 19950317
EP 750614 B1 20010523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 09511238 T2 19971111 JP 1995-524370 19950317
IL 113024 A1 20000726 IL 1995-113024 19950317
ES 2158938 T3 20010916 ES 1995-911342 19950317
PT 750614 T 20011031 PT 1995-911342 19950317
TW 416951 B 20010101 TW 1995-84105132 19950523
US 5798362 A 19980825 US 1996-716160 19960917
GR 3036443 T3 20011130 GR 2001-401292 20010823
PRAI IT 1994-MI506 A 19940318
WO 1995-EP1001 W 19950317
OS MARPAT 124:117340
GI




AB Title compds. [I; R6 = Z1Z2(CR1R2)mR, NMeZr7, 4,4-diphenylpiperidino, etc.; R = aryl(oxy), diarylmethyl, aroyl, etc.; R1,R2 = H, alkyl; R7 = Ph, CHPh2, 4-(2-methoxyphenyl)piperazino; Z = alkylene; Z1 = 1,4-piperazinylenes; Z2 = bond, O, CO, CONH; m = 0-4; n = 0 or 1] were prepared. Thus, I (R6 = piperazino) was amidated by PhCOCH2CO2H to give I (R6 = 2iCOCH2COPh, Z1 = 1,4-piperazinylenes) which had ED25 for blood pressure reduction of 56μg/kg i.v. in normotensid rats and 2.42mg/kg orally

in spontaneously hypertensive rats.
IT 173059-13-7P 173059-43-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-amino-2-piperazinoquinazolines and analogs as α1-adrenergic antagonists)
RN 173059-13-7 CAPLUS
CN 1-Piperazinepropanamide, 4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-β-oxo-N-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

Page 22


JP2004_018717.trn

JP 3218037	B2	20011015		
HU 69702	A2	19950928	HU 1993-2701	19920401
RU 2108325	C1	19980410	RU 1993-58261	19920401
AT 167470	E	19980715	AT 1992-907564	19920401
ZA 9202541	A	19931008	ZA 1992-2541	19920408
US 5453423	A	19950926	US 1993-119202	19930927
NO 9303599	A	19931112	NO 1993-3599	19931008
NO 180165	B	19961118		
NO 180165	C	19970226		
PRAI IT 1991-MI966	A	19910409		
WO 1992-EP724	A	19920401		
OS MARPAT 118:169119				
GI				



AB Title compds. I [X = CH2, S; B = CO, CH2, CH2OCO, CH2OCS, CH2NHCO, CH2NHCS; D = (substituted) Ph, -CH2Ph, -benzhydryl, -5- or 6-membered heterocyclyl, (3-hydroxy-2-pyridyl)methyl; Y = bond, (CH2)2, (CH2)3, CRaRb; Ra, Rb = H, C1-3 alkyl, or CRaRb = C3-6 cycloalkyl; A = free or salfified carboxy group which may be esterified or amidated, C1-3 alkyl, alkanoyl, etc.; A can be cyano when Y = bond] were prepared as antiasthmatics and for the treatment of respiratory tract inflammation. Thus, N-acylation of N-[(pyrrolidin-2-yl)carbonyl]-N'-[4,6-bis(pyrrolidin-1-yl)-1,3,5-triazin-2-yl]piperazine (preparation given) by ClCOCH2CO2Et in MeCN


containing KHC03 at room temperature gave title compound I [D = 4,6-bis(pyrrolidin-1-yl)-1,3,5-triazin-2-yl; B = CO; X = CH2; Y = CH2; A = CO2Et]. I at 2-50 mg/kg in guinea pigs are said to show a protective action in a test of forced expiration of tobacco smoke.
IT 145908-99-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiasthmatic and respiratory tract antiinflammatory)
RN 145908-99-2 CAPLUS
CN 1-Pyrrolidinepropanamide, 2-[[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]carbonyl]-β-oxo-N-2-pyridinyl- (9CI) (CA INDEX NAME)



=> S L18 NOT L19
L20 1 L18 NOT L19

=> D BIB ABS HITSTR


L20 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:154992 CAPLUS
DN 126:199815
TI Synthesis of an Amino Acid Analog To Incorporate p-Aminobenzyl-EDTA in Peptides
AU Song, Anne In.; Rana, Tariq M.
CS Department of Pharmacology Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, 08854, USA
SO Bioconjugate Chemistry (1997), 8(2), 249-252
CODEN: BCCHE5; ISSN: 1043-1802
PB American Chemical Society
DT Journal
LA English
OS CASREACT 126:199815
GI



AB A convenient and straightforward synthesis of an amino acid analog I (Fmoc = 9-fluorenylmethoxycarbonyl), compatible with Fmoc solid phase peptide synthesis strategy is described. I was used to incorporate p-aminobenzyl-EDTA at an internal sequence position in an HIV-1 Tat protein fragment. After cleavage from the resin and standard deprotection,

Page 25

PAGE 1-B



PAGE 1-C

-NH2


the peptide was purified by high-performance liquid chromatog. and characterized by mass spectrometry. Through this methodol., flexible linkers of different lengths and containing various structures can be placed between the α -carbon backbone of peptides and metal chelates. These peptides will provide a new class of affinity cleaving reagents that can be directed against protein and nucleic acid targets.

IT 187671-20-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of a protected aspartic acid aminobenzyl-EDTA conjugate for incorporation into peptides)

RN 187671-20-1 CAPLUS
CN L-Glutamine, L-arginyl-N-(4-(2,3-bis(bis(2-(1,1-dimethylethoxy)-2-oxoethyl)amino)propyl)phenyl)-L-asparaginyl-L-prolyl-L-prolyl-L-glutamylglycyl-L-seryl-L-glutamyl-L-threonyl-L-histidyl-L-glutamyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-lysyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



Page 26

PAGE 2-A




RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> S L4
L21 13 L4
=> S L21 AND P/DT
4628444 P/DT
L22 13 L21 AND P/DT
=> D BIB ABS 1-13

L22 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:857551 CAPLUS
DN 141:350179
TI Preparation of azolidinedicarboxamides and related compounds as Factor VIIa inhibitors and Factor VIIa inhibitors
IN Tsaklakidis, Christos; Dorach, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes
PA Merck Patent GmbH, Germany
SO PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004087646	A2	20041014	WO 2004-EP2350	20040308
WO 2004087646	A3	20050106		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PG, PH, PL, PT, RD, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, GB, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10315377	A1	20041014	DE 2003-10315377	20030403
DE 10329295	A1	20050203	DE 2003-10329295	20030630
PRAI DE 2003-10315377	A	20030403		

DE 2003-10329295 A 20030630
US 2003-483897P P 20030702
OS MARPAT 141:350179
GI



AB R1R2(TYX)EWCOGD (R1, R2 = H, O, halo, A, ethynyl, OR3, N(R3)2, NO2, cyano, N3, CO2R3, CON(R3)2, etc.; R3 = H, A, HC.tplbond.CCH2, MeC.tplbond.CCH2, CH2CH(OH)CH2OH, etc.; R4 = H, A; W = N, C, CR3; E = atoms to form a 3-7 membered (heterocyclic) ring optionally containing a double bond; D = mono- or dinuclear (substituted) (hetero)aryl; G = [C(R4)2]n, [C(R4)2]nNR3, [C(R4)2]nO, [C(R4)2]nS, etc.; n = 0-2; X = [C(R4)2]nCO[C(R4)2]n, [C(R4)2]nNR3[C(R4)2]n, [C(R4)2]nNR3CO[C(R4)2]n, etc.; Y = alkylene, cycloalkylene, heterocyclylene, arenediyl; T = substituted mono- or dinuclear carbocyclyl, heterocyclyl; A = (fluoro-substituted) alkyl optionally interrupted by O, S, CH:CH; were prepared Thus, title compound (I) [preparation from 4-(4-aminophenyl)morpholin-3-one, Boc-D-proline, and 4-chlorophenyl isocyanate given] bound to Factor Xa receptors with IC50 = 1.8 + 10⁻⁸ M.

L22 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:857166 CAPLUS

DN 141:332218

TI Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists

IN Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Tora, George; Vig, Shikha

PA USA

SO U.S. Pat. Appl. Publ., 203 pp., Cont.-in-part of U.S. Ser. Number 445,523. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004204397	A1	20041014	US 2003-729155	20031205
US 2004063735	A1	20040401	US 2003-445523	20030527
US 6843269	B2	20050118	US 2003-454826	20030604
PRAI US 2002-386138P	P	20020605		
US 2002-388617P	P	20020613		
US 2002-389870P	P	20020619		
US 2002-393200P	P	20020701		
US 2002-413534P	P	20020925		
US 2003-445523	A2	20030527		

OS MARPAT 141:332218

GI

Page 29

JP2004_018717.trn

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 6843269 B2 20050118 US 2003-454826 20030604

PRAI US 2002-386138P P 20020605

US 2002-388617P P 20020613


US 2002-389870P P 20020619

US 2002-393200P P 20020701

US 2002-413534P P 20020925

OS MARPAT 140:42208

GI



AB Diazaheterocycles I [m, n = 0-2; m = n = 2; V = (un)substituted NH2, OH; Q = (un)substituted alkyl, NH2, NHCO2H, NHCONH2; U = CH2, NH; D = O, NCM, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic] were prepared for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases,

such as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepared from 1H-indazole-5-carboxaldehyde and had IC50 for calcitonin gene related peptide receptor binding of ≤ 10 nM.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:76556 CAPLUS

DN 138:131125

TI Fat accumulation-modulating compounds

IN Stevenson, Michael John; Leighton, Harry Jefferson

PA Adipogenix, Inc., USA

SO PCT Int. Appl., 96 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007888	A2	20030130	WO 2002-0523295	20020722



AB Diazaheterocycles I [m, n = 0-2; V = (un)substituted NH2, OH; Q = (un)substituted alkyl, NH2, NHCO2H, NHCONH2; U = CH2, NH; D = O, NCM, alkylsulfonylimino; A = C, N, CH; E = (un)substituted heterocyclic; with provisos] were prepared for use as antagonists of calcitonin gene-related peptide receptors for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases,

such

as asthma and chronic obstructive pulmonary disease (COPD). Thus, the indazole II was prepared from 1H-indazole-5-carboxaldehyde and had IC50 for calcitonin gene related peptide receptor binding of ≤ 10 nM. The pharmaceutical composition comprising the compound I is claimed.

L22 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:991516 CAPLUS

DN 140:42208

TI Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists

IN Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Vig, Shikha

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 309 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104236	A1	20031218	WO 2003-US16576	20030527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				

Page 30

JP2004_018717.trn

WO 2003007888 A3 20031127

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG

US 2003144350 A1 20030731 US 2002-201588 20020722

PRAI US 2001-306837P P 20010720

OS MARPAT 138:131125

GI



AB The present invention pertains to compds. effective at modulating fatty acid or triglyceride ("fat") accumulation by cells, such compds. having therapeutic potential as regulators of body mass and for the treatment of overweight individuals, obesity, and metabolic disorders. An example compound is I and protocol for high-throughput screening of compound efficacy

on human preadipocytes is given. Therapeutic methods and pharmaceutical compns. featuring these compds. are also provided.

L22 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:6377 CAPLUS

DN 136:69695

TI Preparation of β -lactam compounds as inhibitors of tryptase

IN Bisacchi, Gregory S.; Slusarchyk, William A.; Treuner, Uwe; Sutton, James C.; Zahler, Robert; Seiler, Steven; Kronenthal, David R.; Randazzo, Michael E.; Schwinden, Mark D.; Xu, Zhongmin; Shi, Zhongping

PA Bristol-Myers Squibb Co., USA

SO U.S., 171 pp., Cont.-in-part of U. S. Ser. Number 336,253, abandoned.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6335324	B1	20020101	US 1999-458847	19991213
PRAI US 1998-90636P	P	19980625		
US 1999-336253	B2	19990618		

OS MARPAT 136:69695
GI

AB Novel β -lactam compds., e.g. of formula I [R = CO₂H, alkoxy-carbonyl, acyl, CO-heterocyclyl, etc.; X = acyl, CO-heterocyclyl, SO₂-alkyl, aminoalkylphenyl, etc.; n = 1-6], are prepared. These compds. inhibit tryptase as well as other enzyme systems or are selective tryptase inhibitors and are useful as antiinflammatory agents particularly in the treatment of chronic asthma (no data). Thus, II was prepared from (4S)-N-(tert-butyl-dimethylsilyl)azetidin-2-one-4-carboxylic acid, 1-chloro-3-iodopropane, N,N'-bis(benzyloxycarbonyl)-1-guanylpiprazole and benzyl isocyanate.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:507689 CAPLUS

DN 135:92860

TI Preparation of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders

IN Rudolf, Klaus; Eberlein, Wolfgang; Dreyer, Alexander; Muller, Stephan Georg; Doods, Henri; Bauer, Eckhart

PA Boehringer Ingelheim Pharma K.-G., Germany

SO PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001049676	A1	20010712	WO 2000-EP13236	20001222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19963868	A1	20010712	DE 1999-19963868	19991230
CA 2395541	AA	20010712	CA 2000-2395541	20001222
BR 2000017063	A	20021022	BR 2000-17063	20001222
EP 1252153	A1	20021030	EP 2000-991806	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519222	T2	20030617	JP 2001-550216	20001222
EE 200200369	A	20031015	EE 2002-369	20001222
BG 106848	A	20021229	BG 2002-106848	20020620

PI	WO 2000009543	A2	20000224	WO 1999-CA736	19990809
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6323180	B1	20011127	US 1999-368866		19990805
CA 2338946	AA	20000224	CA 1999-2338946		19990809
CA 2445938	AA	20000224	CA 1999-2445938		19990809
AU 9952731	A1	20000306	AU 1999-52731		19990809
AU 769738	B2	20040205			
BR 9913646	A	20010605	BR 1999-13646		19990809
EP 1105413	A2	20010613	EP 1999-938084		19990809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200100432	T2	20010921	TR 2001-200100432		19990809
JP 200200129	T2	20020621	JP 2002-200200129		19990809
JP 2002522554	T2	20020723	JP 2000-564993		19990809
EE 200100081	A	20020815	EE 2001-81		19990809
NZ 510396	A	20040227	NZ 1999-510396		19990809
US 6268207	B1	20010731	US 2000-660030		20000912
US 6329379	B1	20011211	US 2000-675398		20000929
US 6329417	B1	20011211	US 2000-703751		20001101
BG 105232	A	20011130	BG 2001-105232		20010208
HR 2001000102	A1	20020228	HR 2001-102		20010208
NO 2001000683	A	20010402	NO 2001-683		20010209
US 2002016442	A1	20020207	US 2001-827976		20010406
US 6420380	B2	20020716			
US 2002037998	A1	20020328	US 2001-849057		20010504
US 6410531	B2	20020625			
US 6534523	B1	20030318	US 2002-91293		20020305
PRAI US 1998-95931P	P	19980810			
US 1999-132386P	P	19990504			
US 1998-132386P	P	19980810			
US 1999-368866	A3	19990805			
CA 1999-2338946	A3	19990809			
WO 1999-CA736	W	19990809			
US 2001-849057	A1	20010504			
OS MARPAT 132:180871					
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Peptides I [R = H, (un)substituted aryl, alkoxy, heterocyclyl, or alkylheterocyclyl, acyl R4CO, carboxylate R4O2C, amide R4NR5CO, thioamide R4NR5C(S), or sulfonyl group R4SO2, where R4 = (un)substituted alkyl, cycloalkyl, cycloalkoxy, amino, aralkyl, or heterocyclyl, with proviso that R4 = cycloalkoxy for amides or thioamides; R5, Y = H, alkyl; R3 = (un)substituted alkyl, cycloalkyl, or alkylcycloalkyl; R2 = (un)substituted cycloalkyl-, aryl-, aralkyl-, or heterocyclylmethyl-, -amino-, -oxy-, or -thio; R1 = H; alkyl, cycloalkyl, alkenyl, or alkynyl, all optionally substituted with halogen] or their racemates.

ZA 2002005181 A 20030930 ZA 2002-5181 20020627
NO 2002003161 A 20020628 NO 2002-3161 20020628
US 2003212057 A1 20031113 US 2002-169009 20021107
PRAI DE 1999-19963868 A 19991230
WO 2000-EP13236 W 20001222
OS MARPAT 135:92860
GI



AB The invention relates to piperidine-substituted α - or β -amino acids (I); R = (un)saturated (un)substituted heterocycle; R1 = Ph, naphthyl, (un)substituted heterocycle; R2 = H, alkyl; A, A1 = H; when one of A or A1 = H, the other = NH₂, 1,4'-bipiperidyl, alkylamino, N(R3)(Z-R4) (forming (substituted) α - or β -amino acid); R3 = H, alkyl; Z = C(O), SO₂; R4 = alkoxy, amino, (di)alkylamino, substituted heterocycle] their tautomers, diastereomers, enantiomers, mixts., and to their salts, in particular, their physiologically compatible salts with inorg. or organic acids or bases, which comprise valuable pharmacol. properties, in particular, CGRP-antagonistic properties. The invention also relates to medicaments containing these compds., to their use and to methods for the production thereof;

formulations were given. Preparation of fragments CO₂H(R2)AC(O)R1, and A

or

A1 substituents were given. Thus (R,S)-4-(4-amino-3,5-dibromophenyl)-2-[[1,1-dimethylethoxy carbonyl)methylamino]-4-oxo-butanoic acid was reacted with 3-(piperidinyl)-1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one to give I (R = 1,3,4,5-tetrahydro-1,3-benzodiazepin-2(2H)-one; R1 = 4-amino-3,5-dibromophenyl; R2 = H; A = (1,1-dimethylethoxy carbonyl)methylamino; A1 = H). In in vitro tests using SK-N-MC cells as tests of human CGRP-receptor binding affinity, I had IC₅₀ \leq 10000 nM, and acted as CGRP antagonists at dosages between 10⁻¹¹ - 10⁻⁵ M.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:133714 CAPLUS

DN 132:180871

TI Preparation of hepatitis C inhibitory tripeptides

IN Llinas-Brunet, Montse; Bailey, Murray D.; Cameron, Dale; Faucher, Anne-Marie; Ghirelli, Elise; Goudreau, Nathalie; Halmos, Teddy; Poupard, Marc-Andre; Rancourt, Jean; Tsantrizos, Youla S.; Wernic, Dominik M.; Simoneau, Bruno

PA Boehringer Ingelheim (Canada) Ltd., Can.

SO PCT Int. Appl., 168 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

diastereoisomers, and optical isomers were prepared as hepatitis C virus (HCV) inhibitory tripeptides. Thus, compound II was prepared via peptide coupling reactions in solution and showed IC₅₀ < 0.5 μ M in the recombinant HCV NS3 protease/NS4A cofactor peptide radiometric assay.

L22 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:542334 CAPLUS

DN 127:225293

TI Pharmaceutical compositions containing pyrrolidine derivatives for the treatment of drug abuse

IN Bohme, Andreas; Capet, Marc; Dubroeuq, Marie-Christine; Fratta, Walter; Guyon, Claude; Imperato, Assunta

PA Rhone-Poulenc Rorer SA, Fr.; Bohme, Andreas; Capet, Marc; Dubroeuq, Marie-Christine; Fratta, Walter; Guyon, Claude; Imperato, Assunta

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9728799	A1	19970814	WO 1997-FR210	19970203
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, NA, NZ, NO, PL, RO, SG, SI, SK, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2744362	A1	19970808	FR 1996-1482	19960207
FR 2744362	B1	19980227		
AU 9717273	A1	19970828	AU 1997-17273	19970203
PRAI FR 1996-1482	A	19960207		
WO 1997-FR210	W	19970203		
OS MARPAT 127:225293				

AB Pharmaceutical compns. containing pyrrolidine deriva. (Markush structure given), isomers or salts thereof, are useful for the treatment of abuse of drugs or psychomimetics, e.g. narcotics and hallucinogens. An example is [(tert-butoxycarbonyl-4-cyclohexyl-2-thiazolidinyl-3)-2-oxo-2-ethyl]-3-ureido]-3-phenylacetic-(4R) acid. A tablet contained a pyrrolidine derivative

50, lactose 104, cellulose 40, polyvidone 10, sodium carboxymethyl starch 22, talc 10, magnesium stearate 2, colloidal silica 2, and a mixture of hydroxymethyl cellulose, glycerin, titanium oxide q.s. 245 mg.

L22 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:211766 CAPLUS

DN 124:260823

TI Preparation of pyrrolidine derivatives as cholecystokinin and gastrin receptor ligands

IN Capet, Marc; Dubroeuq, Marie-Christine

PA Rhone-Poulenc Rorer S.A., Fr.

SO PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9535310	A1	19951228	WO 1995-FR796	19950616
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG,				

EP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

FR 2721314 A1 19951222 FR 1994-7540 19940620
FR 2721314 B1 19960719
AU 9527966 A1 19960115 AU 1995-27966 19950616
EP 766695 A1 19970409 EP 1995-923397 19950616
EP 766695 B1 19980722

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
JP 10501802 T2 19980217 JP 1995-501747 19950616
AT 168697 E 19980815 AT 1995-923397 19950616
ES 2119454 T3 19981001 ES 1995-923397 19950616
ZA 9505052 A 19960209 ZA 1995-5052 19950619
US 5716936 A 19980210 US 1996-750653 19961218
PRAI FR 1994-7540 A 19940620
WO 1995-FR796 W 19950616

OS MARPAT 124:260823
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; R = (cyclo)alk(en)yl, phenylalkyl, heteroaryl, etc.; R1, R3, R4 = H, alkyl; R2 = carboxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, (di)alkylaminoalkyl, etc.; R5 = (un)substituted phenyl(amino), indolyl, quinolyl; R6 = H, (phenyl)alkyl; R7 = alkylsulfonyl, SO2NHR8R9, SO2Ph, etc.; R8 = H, alkyl, phenyl(alkyl); R9 = alkyl, phenyl(alkyl)] were prepared

Thus, 2-FC6H4CH:NCH2CO2CMe3 was cyclocondensed with 4-ClC6H4SO2CH:CH2 (preparation each given) and 1 of the enantiomeric products N-acylated with 3-(MeO2CCH2)C6H4NHCONHCH2CO2H (preparation given) to give title compound (RS,4SR,5RS)-II. I had IC50 of ≤ 2000 nM for CCK receptor binding.

L22 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1994:217658 CAPLUS

DN 120:217658

TI Preparation and formulation of 2-aryl-3-(ureidoacetyl)thiazolidine-4-carboxylates and analogs as CCK receptor and gastrin receptor ligands

IN Capet, Marc; Cotrel, Claude; Guyon, Claude; Joannic, Michel; Manfre, Franco; Roussel, Gerard; Dubroeuq, Marie Christine; Cheva, Michel; Dutruc-Rossat, Gilles

PA Rhone-Poulenc Rorer SA, Fr.

SO PCT Int. Appl., 186 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9301167	A1	19930121	WO 1992-FR626	19920703
W: AU, CA, CS, FI, HU, JP, KR, NO, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
FR 2678938	A1	19930115	FR 1991-8675	19910710
FR 2678938	B1	19931008		
EP 527069	A1	19930210	EP 1992-401904	19920703
R: PT				
AU 9223275	A1	19930211	AU 1992-23275	19920703

Page 37

AU 662345 B2 19950831
EP 593639 A1 19940427 EP 1992-915456 19920703
EP 593639 B1 19950405

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
JP 06509331 T2 19941020 JP 1992-502018 19920703
JP 3034043 B2 20000417
AT 120732 E 19950415 AT 1992-915456 19920703
ES 2071510 T3 19950616 ES 1992-915456 19920703
HU 70403 A2 19951030 HU 1994-61 19920703
PL 171054 B1 19970228 PL 1992-313380 19920703
PL 171094 B1 19970328 PL 1992-313379 19920703
PL 171112 B1 19970328 PL 1992-313381 19920703
PL 171095 B1 19970328 PL 1992-313382 19920703
PL 171333 B1 19970430 PL 1992-302029 19920703
CZ 283602 B6 19980513 CZ 1994-49 19920703
RU 2118316 C1 19980827 RU 1994-15258 19920703
CA 2102697 C 20030930 CA 1992-2102697 19920703
ZA 9205128 A 19930428 ZA 1992-5128 19920709
NO 9304300 A 19931126 NO 1993-4300 19931126
NO 180166 B 19961118
NO 180166 C 19970226
FI 105190 B1 20000630 FI 1994-72 19940107
US 5610144 A 19970311 US 1994-175381 19940627
PRAI FR 1991-8675 A 19910710
WO 1992-FR626 A 19920703

OS MARPAT 120:217658
GI



AB Title compds. [I; Z = CH2, CH2CH2, SOO-2, CHOH and R1 = (substituted) (hetero)aryl; Z = CH2, R1 = H, and R5 = Ph; Z = CHPh and R1 = R5 = H; R2 = alkoxyalkyl, CONH2, Ph, etc.; R3 = (substituted) phenylamino, Ph, etc.; R4 = H, alkyl] were prepared. Thus, L-HSCH2CH(NH2)CO2H was cyclocondensed with PhCHO and the esterified product N-acetylated with Me3CO2CNHCH2CO2H to give, after silica chromatog. and deprotection, thiazolidinecarboxylate (2R,4R)-II (III; R = H). The latter was condensed with 3-MeC6H4NCO to give III (R = CONHC6H4Me-3). I had IC50 ≤ 1 mM for inhibition of binding at CCK receptors. Prepare of a chiral HPLC phase for optical resolution of I is given.

L22 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:256054 CAPLUS

DN 116:256054

TI Preparation of peptide-linked 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles and related compounds as inhibitors of cholecystokinin and gastrin

IN Molino, Bruce F.; Darkes, Paul R.; Ewing, William R.

PA Rorer International (Holdings), Inc., USA

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2



DT Patent

Page 38

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9200295	A1	19920109	WO 1991-US4236	19910613
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
US 5162336	A	19921110	US 1990-573514	19900824
CA 2068887	AA	19911222	CA 1991-2068887	19910613
AU 9186116	A1	19920123	AU 1991-86116	19910613
AU 640277	B2	19930819		
EP 491943	A1	19920701	EP 1991-916717	19910613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
PRAI US 1990-542495	A	19900621		
US 1990-573514	A2	19900824		
WO 1991-US4236	A	19910613		
OS MARPAT 116:256054				
GI				



AB Title compds. [I; X = aryl; Y = H, alkyl, (substituted) aralkyl, acyl, aroyl, heterocyclylcarbonyl, carbamoyl, alkoxyalkyl, aryloxyalkyl, alkoxyalkoxyalkyl; Z = (substituted) N-containing heterocyclyl, amino, amino acid residue, peptide residue, etc.; m = 0-3; n = 0-4], were prepared

Thus, (3R)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole-3-carboxylic acid in THF at -15° was treated with Et3N and N,N-bis[2-oxo-3-oxazolinyl]phosphorodiamidic chloride followed by stirring for 20 min. Benzyl N-(L-prolyl)nipecotate was added and the mixture was stirred overnight at ice temperature to give the amide, which was

deprotected with CF3CO2H followed by acylation with 3,4-dichlorophenyl isocyanate and hydrogenolysis to give title compound II. II bound to CCK-A, CCK-B, and gastrin receptors with IC50's of 10, 0.111, and 0.026 μ M, resp.

L22 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1988:570130 CAPLUS

DN 109:170130

TI Preparation and formulation of novel mitomycin derivatives as antitumor agents

IN Muto, Kenji; Kuroda, Tokuyuki; Morimoto, Makoto

PA Kyowa Hakkō Kogyo Co., Ltd., Japan

SO Japan Kokai Tokkyo Koho, 13 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63035575	A2	19880216	JP 1986-181012	19860731
PRAI JP 1986-181012				
OS MARPAT 109:170130				
GI				



AB The title compds. I [A = dipeptide, tripeptide residue; R1 = NH2, OMe; one of R2 and R3 is R4CO, R4OCO, R4SO2, R4NHCO, R5S, the other is H; R4 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl, aralkyl; R5 = substituted aryl, heterocyclyl; or R2R3 = Q; R6 = arylene], useful as antitumor agents, were prepared. Condensation of tert-butyloxycarbonyl-L-alanyl-L-proline with mitomycin C in the presence of dicyclohexylcarbodiimide gave 93% I (R1 = NH2, R2 = Me3COCO, R3 = H, A = L-alanyl-L-prolyl) (II). II exhibited an ED50 of 7.3 mg/kg against transplanted sarcoma 180 tumor in mice, vs. an ED50 of 2.9-3.9 mg/kg for mitomycin C.

L22 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1986:443340 CAPLUS

DN 105:43340

TI Tripeptide derivatives for use as antihypertensive agents

IN Eguchi, Chikahiko; Kurauchi, Masahiko; Sakakibara, Shumpei

PA Ajinomoto Co., Inc., Japan

SO Eur. Pat. Appl., 47 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 173510	A2	19860305	EP 1985-305727	19850813
EP 173510	A3	19870916		
R: CH, DE, FR, GB, IT, LI				
JP 61053298	A2	19860317	JP 1984-176355	19840824
JP 06055758	B4	19940727		
US 4719200	A	19880112	US 1985-769029	19850826
PRAI JP 1984-176355	A	19840824		
GI				

R1NR2CR3R4CON—CON—COR5 I

AB Peptides (I; R1 = H, hydrocarbyl, acyl; R2 = H, hydrocarbyl, acyl, thioacyl, esterified CO₂H, carbamoyl, hydrocarbyloxy, NO₂, etc.; R3 and R4 = H, alkyl, aryl, aralkyl; R5 = OH, hydrocarbyloxy, hydrocarbylthio, amino, acylamino, etc.), which exhibited antihypertensive activity, were prepared. H-Ala-Pro-Pro-OH was treated with ClCO₂Et and NaOH to give EtO₂C-Ala-Pro-Pro-OH.

=> LOG Y

COST IN JAPANESE YEN

SINCE FILE	TOTAL
ENTRY	SESSION
11102	74423

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2068	-2068

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:56:42 ON 08 FEB 2005

Host Name: +++

OK

OK

Dialing COMPUERVE at 0070670488888

OK

CONNECT 46667

Connecting through CompuServe

0076TEW

Host Name: STNT

Connected to 0000 CAA_0

Welcome to STN International! Enter x:x
LOGINID:TKYBAJ74
PASSWORD:
TERMINAL (ENTER 1, 2, 3, EUC, SJIS OR ?):2

***** Welcome to STN International *****

Item	Date	Headline
NEWS 1		STN, CAS FILES Workshop Schedule in Japan
NEWS 2	Oct 26	KOREAPAT now available on STN
NEWS 3	Nov 19	Current-awareness alerts, saved answer sets, and current search transcripts to be affected by CERAB, COMPUAB, ELCOM, and SOLIDSTATE reloads
NEWS 4	Nov 22	November 22, 2004 LISA new on STN
NEWS 5	Dec 1	PHAR reloaded with additional data
NEWS 6	Dec 15	12 databases to be removed from STN on 31, Dec., 2004
NEWS 7	Dec 17	MEDLINE update schedule for December 2004
NEWS 8	Dec 20	ELCOM reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 9	Dec 20	COMPUAB reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 10	Dec 20	SOLIDSTATE reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 11	Dec 20	CERAB reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 12	Dec 20	Three new fields added to IFIPAT/IFIUDB/IFICDB
NEWS 13	Dec 27	EPFULL: New patent full text database to be available on STN
NEWS 14	Dec 31	CAPLUS - PATENT COVERAGE EXPANDED
NEWS 15	Jan 1	No connect-hour charges in EPFULL during January and February 2005
NEWS 16	Jan 5	Urgent announcement to STN customers accessing via phone line WorldCom access points were changed
NEWS 17	Jan 12	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS HOURS		STN operating Hours
NEWS WORLDCOM		STN High Speed Access via Worldcom
NEWS INTER		INTERNET ACCESS to STNT(STN-Tokyo)

Page 1

NEWS EXPRESS STN Express 7.0 with Discover!
(Windows) Now available!
NEWS WWW STN Tokyo World Wide Web Site

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:02:50 ON 09 FEB 2005

	SINCE FILE	TOTAL
COST IN JAPANESE YEN	ENTRY	SESSION
FULL ESTIMATED COST	36	36

FILE 'REGISTRY' ENTERED AT 11:03:01 ON 09 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)
CHARGED TO COST=4PRD

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0
DICTIONARY FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> ACT RD018717/A
L1 STR
L2 STR
L3 349 SEA FILE=REGISTRY SSS FUL L1 AND L2

	SINCE FILE	TOTAL
COST IN JAPANESE YEN	ENTRY	SESSION
FULL ESTIMATED COST	65	101

FILE 'CAPLUS' ENTERED AT 11:03:23 ON 09 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
CHARGED TO COST=4PRD

Page 2

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Feb 2005 VOL 142 ISS 7
FILE LAST UPDATED: 7 Feb 2005 (20050207/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> S L3
L4 13 L3
=> D BIB_HITSTR 1-13

L4 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:857551 CAPLUS
DN 141:350179
TI Preparation of azolidinedicarboxamides and related compounds as Factor Xa and Factor VIIa inhibitors
IN Tsaklakidis, Christos; Dorach, Dieter; Mederski, Werner; Cezanne, Bertram; Gleitz, Johannes
PA Merck Patent GmbH, Germany
SO PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CMT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004087646	A2	20041014	WO 2004-EP2350	20040308
WO 2004087646	A3	20050106		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10315377	A1	20041014	DE 2003-10315377	20030403
DE 10329295	A1	20050203	DE 2003-10329295	20030630
PRAI DE 2003-10315377	A	20030403		
DE 2003-10329295	A	20030630		
US 2003-483897P	P	20030702		
OS MARPAT 141:350179				
IT 774602-65-2P 774602-69-6P 774602-70-9P 774602-71-0P 774602-72-1P				
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				


(preparation of azolidinedicarboxamides and related compds. as Factor Xa and Factor VIIa inhibitors)
RN 774602-65-2 CAPLUS
CN 1-Pyrrolidinedicarboxamide, N-(4-chlorophenyl)-4-hydroxy-2-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774602-69-6 CAPLUS
CN 1-Pyrrolidinedicarboxamide, N-(4-chlorophenyl)-4-hydroxy-2-[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774602-70-9 CAPLUS
CN 1-Pyrrolidinedicarboxamide, N-(4-chlorophenyl)-2-[[4-(4-ethyl-1-piperazinyl)-1-piperidinyl]carbonyl]-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 774602-71-0 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-2-[[4-(4,6-dimethyl-2-pyrimidinyl)-1-piperazinyl]carbonyl]-4-hydroxy-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 774602-72-1 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-4-hydroxy-2-[[4-(1-methyl-4-piperidinyl)-1-piperazinyl]carbonyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:857166 CAPLUS
DN 141:332218
TI Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists
IN Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Jiang, Xiang Jun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Tora, George; Vig, Shikha
PA USA
SO U.S. Pat. Appl. Publ., 203 pp., Cont.-in-part of U.S. Ser. Number 445,523.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2
PATENT NO. _____ KIND _____ DATE _____ APPLICATION NO. _____ DATE _____

Page 5


RN 635711-75-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(2,4,5-trimethylphenyl)amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-76-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-77-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(phenylamino)carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)


PI US 2004204397 A1 20041014 US 2003-729155 20031205
US 2004063735 A1 20040401 US 2003-445523 20030527
US 6843269 B2 20050118 US 2003-454826 20030604
PRAI US 2002-386138P P 20020605
US 2002-388617P P 20020613
US 2002-389870P P 20020619
US 2002-393200P P 20020701
US 2002-413534P P 20020925
US 2003-445523 A2 20030527
OS MARPAT 141:332218
IT 635711-72-7P 635711-75-0P 635711-76-1P
635711-77-2P 635711-78-3P 635711-79-4P
635711-80-7P 635711-82-9P 635711-83-0P
635711-84-1P 635711-86-3P 635711-87-4P
635711-88-5P 635711-89-6P 635711-90-9P
635711-92-1P 635711-93-2P 635711-94-3P
635711-95-4P 635711-96-5P 635711-97-6P
635711-98-7P 635711-99-8P 635712-00-4P
635712-01-5P 635712-02-6P 635712-04-8P
635712-05-9P 635712-08-2P 635712-09-3P
635712-10-6P 635712-11-7P 635712-12-8P
635712-13-9P 635712-14-0P 635712-15-1P
635712-16-2P 635712-17-3P 635712-19-5P
635712-20-8P 635712-22-0P 635712-23-1P
635712-24-2P 635712-25-3P 635712-26-4P
635712-27-5P 635712-28-6P 635712-29-7P
635712-30-0P 635712-31-1P 635712-32-2P
635712-33-3P 635712-34-4P 635712-35-5P
635712-38-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

RN 635711-72-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(2-phenoxyphenyl)amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Page 6


piperidinyl]-2-[[[(2-methylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-78-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(3-ethylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-79-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(phenylamino)carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-80-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[1,1'-biphenyl]-4-ylamino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-82-9 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[4-phenoxyphenyl]amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 9

JP2004_018717_2.trn




RN 635711-86-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2-methoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-87-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[3-methoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-83-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[3-acetylphenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-84-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[2,3-dichlorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 10

JP2004_018717_2.trn




RN 635711-88-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2,3-dimethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-89-6 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-90-9 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-92-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2,4-dimethoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 13

JP2004_018717_2.trn




RN 635711-95-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[3,4-dimethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-96-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[3,5-dichlorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-93-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[2,4-difluorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-94-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2,5-dimethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 14

JP2004_018717_2.trn




RN 635711-97-6 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-98-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[2,4-dichlorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-99-8 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-00-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,6-difluorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Page 17



RN 635712-01-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,6-dichloro-4-pyridinyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-02-6 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(3,5-dimethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Page 18




RN 635712-04-8 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2-chloro-5-(trifluoromethyl)phenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-05-9 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(2,3,4-trifluorophenyl)amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-08-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2-fluorophenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-09-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2-chlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-10-6 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,5-dichlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-11-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2,5-dimethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]-9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 21

JP2004_018717_2.trn




RN 635712-14-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(3-fluorophenyl)amino]carbonyl]amino]-1,4-dioxobutyl]-9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-15-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-12-8 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2-ethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]-9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-13-9 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-bromophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 22

JP2004_018717_2.trn




RN 635712-16-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(4-bromophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-17-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(4-fluorophenyl)amino]carbonyl]amino]-1,4-dioxobutyl]-9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-19-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[4-methoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-20-8 CAPLUS
CN Benzoic acid, 4-[[[[(1S)-1-[[[4-(1,4'-bipiperidin]-1'-ylcarbonyl)-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-22-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[2,5-difluorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-23-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2,4-dimethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-24-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[3-chloro-4-methylphenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-25-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[5-chloro-2-methoxyphenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-26-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-chloro-2-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-27-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[4-ethoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-28-6 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[4-ethoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-29-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-chloro-2-methylphenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Page 29




RN 635712-32-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-bromo-2-methylphenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-33-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[5-fluoro-2-methylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-30-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[3-chloro-2-methylphenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-31-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[3-chloro-4-fluorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Page 30




RN 635712-34-4 CAPLUS
CN Benzoic acid, 3-[[[1S)-1-[(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-35-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[1,1'-biphenyl]-2-ylamino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-38-8 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[2-(trifluoromethoxy)phenyl]amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:991516 CAPLUS
DN 140:42208
TI Preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists
IN Chaturvedula, Prasad V.; Chen, Ling; Civiello, Rita; Conway, Charles Mark; Degnan, Andrew P.; Dubowchik, Gene M.; Han, Xiaojun; Karageorge, George N.; Luo, Guanglin; Macor, John E.; Poindexter, Graham; Vig, Shikha
PA Bristol-Myers Squibb Company, USA


Page 33

JP2004_018717_2.trn



RN 635711-75-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[2,4,5-trimethylphenyl]amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-76-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-(4-chlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

SO PCT Int. Appl., 309 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003104236	A1	20031218	WO 2003-US16576	20030527
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 6843269	B2	20050118	US 2003-454826	20030604
PRAI US 2002-386138P	P	20020605		
US 2002-388617P	P	20020613		
US 2002-389870P	P	20020619		
US 2002-393200P	P	20020701		
US 2002-413534P	P	20020925		
OS MARPAT 140:42208				
IT 635711-72-7P 635711-75-0P 635711-76-1P				
635711-77-2P 635711-78-3P 635711-79-4P				
635711-80-7P 635711-82-9P 635711-83-0P				
635711-84-1P 635711-86-3P 635711-87-4P				
635711-88-5P 635711-89-6P 635711-90-9P				
635711-92-1P 635711-93-2P 635711-94-3P				
635711-95-4P 635711-96-5P 635711-97-6P				
635711-98-7P 635711-99-8P 635712-00-4P				
635712-01-5P 635712-02-6P 635712-04-8P				
635712-05-9P 635712-08-2P 635712-09-3P				
635712-10-6P 635712-11-7P 635712-12-8P				
635712-13-9P 635712-14-0P 635712-15-1P				
635712-16-2P 635712-17-3P 635712-19-5P				
635712-20-8P 635712-22-0P 635712-23-1P				
635712-24-2P 635712-25-3P 635712-26-4P				
635712-27-5P 635712-28-6P 635712-29-7P				
635712-30-0P 635712-31-1P 635712-32-2P				
635712-33-3P 635712-34-4P 635712-35-5P				
635712-38-8P				


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diazaheterocycles as calcitonin gene related peptide receptor antagonists)

RN 635711-72-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[2-(phenoxyphenyl)amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 34

JP2004_018717_2.trn




RN 635711-77-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2-methylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-78-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[3-ethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-79-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[phenylamino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-80-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[1,1'-biphenyl]-4-ylamino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 37

JP2004_018717_2.trn




RN 635711-84-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[2,3-dichlorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-86-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2-methoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-82-9 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[4-phenoxyphenyl]amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-83-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[3-acetylphenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 38

JP2004_018717_2.trn




RN 635711-87-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[3-methoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-88-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2,3-dimethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-89-6 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-90-9 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[(2S)-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]aminobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 41

JP2004_018717_2.trn




RN 635711-94-3 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[(2S)-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[2,5-dimethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-95-4 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[(2S)-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[3,4-dimethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-92-1 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[(2S)-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[2,4-dimethoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-93-2 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[2,4-difluorophenyl]amino]carbonyl]amino]-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 42

JP2004_018717_2.trn




RN 635711-96-5 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[3,5-dichlorophenyl]amino]carbonyl]amino]-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-97-6 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[(2S)-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]aminobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635711-98-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,4-dichlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635711-99-8 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(4-(1-methylethyl)phenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 45

JP2004_018717_2.trn




RN 635712-02-6 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(3,5-dimethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-04-8 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2-chloro-5-(trifluoromethyl)phenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-00-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,6-difluorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-01-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,6-dichloro-4-pyridinyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 46

JP2004_018717_2.trn




RN 635712-05-9 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(2,3,4-trifluorophenyl)amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-08-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2-fluorophenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-09-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2-chlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-10-6 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,5-dichlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 49

JP2004_018717_2.trn




RN 635712-13-9 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-bromophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-14-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(3-fluorophenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-11-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2,5-dimethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-12-8 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2-ethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 50

JP2004_018717_2.trn




RN 635712-15-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chlorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-16-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(4-bromophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-17-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[4-(4-fluorophenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-19-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[4-(4-methoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 53

JP2004_018717_2.trn




RN 635712-23-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2,4-dimethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-24-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-(3-chloro-4-methylphenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-20-8 CAPLUS
CN Benzoic acid, 4-[[[[(1S)-1-[(1,4'-bipiperidin)-1'-ylcarbonyl]-3-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-22-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[2,5-difluorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Page 54

JP2004_018717_2.trn




RN 635712-25-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[5-chloro-2-methoxyphenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-26-4 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-chloro-2-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-27-5 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(4-ethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-28-6 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(4-ethylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Page 57




RN 635712-31-1 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chloro-4-fluorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-32-2 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(4-bromo-2-methylphenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-29-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(4-chloro-2-methylphenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 635712-30-0 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chloro-2-methylphenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Page 58




RN 635712-33-3 CAPLUS
CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(5-fluoro-2-methylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-34-4 CAPLUS
CN Benzoic acid, 3-[[[(1S)-1-[(1,4'-bipiperidin-1'-yl)carbonyl]-3-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 635712-35-5 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(1,1'-biphenyl)-2-ylamino]carbonyl]amino]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 635712-38-8 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[2-(trifluoromethoxy)phenyl]amino]carbonyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Page 61

JP2004_018717_2.trn




L4 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS on STM
 AN 2002:6377 CAPLUS
 DN 136:69695
 TI Preparation of β -lactam compounds as inhibitors of tryptase
 IN Bisacchi, Gregory S.; Slusarchyk, William A.; Treuner, Uwe; Sutton, James C.; Zahler, Robert; Seiler, Steven; Kronenthal, David R.; Randazzo, Michael E.; Schwinden, Mark D.; Xu, Zhongmin; Shi, Zhongping
 PA Bristol-Myers Squibb Co., USA
 SO U.S., 171 pp., Cont.-in-part of U. S. Ser. Number 336,253, abandoned.
 CODEN: USXXAM

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6335324	B1	20020101	US 1999-458847	19991213
PRAI US 1998-90636P	P	19980625		
US 1999-336253	B2	19990618		
OS MARPAT 136:69695				
IT 384829-75-8P				


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of β -lactam compds. as inhibitors of tryptase)
 RN 384829-75-8 CAPLUS
 CN 2-Azetidinocarboxylic acid, 3-[[[1-(aminoiminomethyl)-3-piperidinyl]methyl]-4-oxo-1-[[4-[[[(phenylamino)carbonyl]amino]acetyl]-1-piperazinyl]carbonyl]- (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STM
 AN 2001:507689 CAPLUS



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2005 ACS on STM
 AN 2003:76556 CAPLUS
 DN 138:131125
 TI Fat accumulation-modulating compounds
 IN Stevenson, Michael John; Leighton, Harry Jefferson
 PA Adipogenix, Inc., USA
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003007888	A2	20030130	WO 2002-US23295	20020722
WO 2003007888	A3	20031127		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003144350	A1	20030731	US 2002-201588	20020722
PRAI US 2001-306837P	P	20010720		
OS MARPAT 138:131125				
IT 491868-44-1				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(fat accumulation-modulating compds.)				
RN 491868-44-1 CAPLUS				
CN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI) (CA INDEX NAME)				


Page 62

JP2004_018717_2.trn

DN 135:92860
 TI Preparation of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders
 IN Rudolf, Klaus; Eberlein, Wolfgang; Dreyer, Alexander; Muller, Stephan
 PA Boehringer Ingelheim Pharma K.-G., Germany
 SO PCT Int. Appl., 153 pp.
 CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001049676	A1	20010712	WO 2000-EP13236	20001222
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 19963868	A1	20010712	DE 1999-19963868	19991230
CA 2395541	AA	20010712	CA 2000-2395541	20001222
BR 2000017063	A	20021022	BR 2000-17063	20001222
EP 1252153	A1	20021030	EP 2000-991806	20001222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003519222	T2	20030617	JP 2001-550216	20001222
EE 200200369	A	20031015	EE 2002-369	20001222
BG 106848	A	20021229	BG 2002-106848	20020620
ZA 2002005181	A	20030930	ZA 2002-5181	20020627
NO 2002003161	A	20020628	NO 2002-3161	20020628
US 2003212057	A1	20031113	US 2002-169009	20021107
PRAI DE 1999-19963868	A	19991230		
WO 2000-EP13236	W	20001222		
OS MARPAT 135:92860				
IT 349535-73-5P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of piperidine-substituted amino-acids for use in treatment of CGRP-mediated disorders)				

of
 CGRP-mediated disorders)
 RN 349535-73-5 CAPLUS
 CN Piperidine, 1-[4-(4-amino-3,5-dibromophenyl)-1,4-dioxo-2-[[[2-pyridinylamino]carbonyl]amino]butyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:133714 CAPLUS
DN 132:180871
TI Preparation of hepatitis C inhibitory tripeptides
IN Llinas-Brunet, Montse; Bailey, Murray D.; Cameron, Dale; Faucher, Anne-Marie; Ghio, Elise; Goudreau, Nathalie; Halmos, Teddy; Poupart, Marc-Andre; Rancourt, Jean; Tsantirizos, Youla S.; Wernic, Dominik M.; Simoneau, Bruno
PA Boehringer Ingelheim (Canada) Ltd., Can.
SO PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009543	A2	20000224	WO 1999-CA736	19990809
WO 2000009543	A3	20000525		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6323180	B1	20011127	US 1999-368866	19990805
CA 2338946	AA	20000224	CA 1999-2338946	19990809
CA 2445938	AA	20000224	CA 1999-2445938	19990809
AU 9952731	A1	20000306	AU 1999-52731	19990809
AU 769738	B2	20040205		
BR 9913646	A	20010605	BR 1999-13646	19990809
EP 1105413	A2	20010613	EP 1999-938084	19990809
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
TR 200100432	T2	20010921	TR 2001-200100432	19990809
TR 200200129	T2	20020621	TR 2002-200200129	19990809
JP 2002522554	T2	20020723	JP 2000-564993	19990809
EE 200100081	A	20020815	EE 2001-81	19990809


NZ 510396	A	20040227	NZ 1999-510396	19990809
US 6268207	B1	20010731	US 2000-660030	20000912
US 6329379	B1	20011211	US 2000-675398	20000929
US 6329417	B1	20011211	US 2000-703751	20001101
BG 105232	A	20011130	BG 2001-105232	20010208
HR 2001000102	A1	20020228	HR 2001-102	20010208
NO 2001000683	A	20010402	NO 2001-683	20010209
US 2002016442	A1	20020207	US 2001-827976	20010406
US 6420380	B2	20020716		
US 2002037998	A1	20020328	US 2001-849057	20010504
US 6410531	B2	20020625		
US 6534523	B1	20030318	US 2002-91293	20020305
PRAI US 1998-95931P	P	19980810		
US 1999-132386P	P	19990504		
US 1998-132386P	P	19980810		
US 1999-368866	A3	19990805		
CA 1999-2338946	A3	19990809		
NO 1999-CA736	W	19990809		
US 2001-849057	A1	20010504		
OS MARPAT 132:180871				
IT 259216-26-7P 259216-43-8P				
RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
(preparation of hepatitis C inhibitory tripeptides)				
RN 259216-26-7 CAPLUS				
CN Cyclopropanecarboxylic acid, 3-methyl-N-[(phenylamino)carbonyl]-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 259216-43-8 CAPLUS
CN Cyclopropanecarboxylic acid, N-[(2,6-dimethylphenyl)amino]carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1997:542334 CAPLUS
DN 127:225293
TI Pharmaceutical compositions containing pyrrolidine derivatives for the treatment of drug abuse
IN Bohme, Andreas; Capet, Marc; Dubroeuq, Marie-Christine; Fratta, Walter; Guyon, Claude; Imperato, Assunta
PA Rhone-Poulenc Rorer SA, Fr.; Bohme, Andreas; Capet, Marc; Dubroeuq, Marie-Christine; Fratta, Walter; Guyon, Claude; Imperato, Assunta
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9728799	A1	19970814	WO 1997-FR210	19970203
W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
FR 2744362	A1	19970808	FR 1996-1482	19960207
FR 2744362	B1	19980227		
AU 9717273	A1	19970828	AU 1997-17273	19970203
PRAI FR 1996-1482	A	19960207		
WO 1997-FR210	W	19970203		
OS MARPAT 127:225293				
IT 175153-95-4 195002-44-9 195002-46-1				
RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
(pharmaceutical compns. containing pyrrolidine derivs. for treatment of drug abuse)				
RN 175153-95-4 CAPLUS				
CN Proline, 1-[N-[(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(2-fluorophenyl)-4-(4-morpholinesulfonyl)-, 2-(1,1-dimethylethyl) ester, (2a,4b,5a)- (9CI) (CA INDEX NAME)				

Relative stereochemistry.




RN 195002-44-9 CAPLUS
CN Benzoic acid, 3-[[[2-[5-[(3,3-dimethyl-1-piperidinyl)carbonyl]-2-(2-fluorophenyl)-3-(phenylsulfonyl)-1-pyrrolidinyl]-2-oxoethyl]amino]carbonyl]amino]-, (2a,3b,5a)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 195002-46-1 CAPLUS
CN D-Proline, N-[(3-carboxyphenyl)amino]carbonyl]glycyl-5-phenyl-4-(1-pyrrolidinylcarbonyl)-, 2-(1,1-dimethylethyl) ester, (4S,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 195002-52-9 CAPLUS
CN D-Proline, N-[[[(3-carboxyphenyl)amino]carbonyl]glycyl-5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-, 2-(1,1-dimethylethyl) ester, (4S,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



L4 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:211766 CAPLUS
DN 124:260823
TI Preparation of pyrrolidine derivatives as cholecystokinin and gastrin receptor ligands
IN Capet, Marc; Dubroeuq, Marie-Christine
PA Rhone-Poulenc Rorer S.A., Fr.
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 9535310 A1 19951228 WO 1995-FR796 19950616
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU,


Page 69

JP2004_018717_2.trn



IT 175154-29-7P 175154-31-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolidine derivs. as cholecystokinin and gastrin receptor ligands)
RN 175154-29-7 CAPLUS
CN Proline, 5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-1-[[[(3-(phenylmethoxy)carbonyl)phenyl]amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, (2α,4β,5α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 175154-31-1 CAPLUS

SG, SI, SK, TJ, TH, TT, UA, US, UZ, VN
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
FR 2721314 A1 19951222 FR 1994-7540 19940620
FR 2721314 B1 19960719
AU 9527966 A1 19960115 AU 1995-27966 19950616
EP 766695 A1 19970409 EP 1995-923397 19950616
EP 766695 B1 19980722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
JP 10501802 T2 19980217 JP 1995-501747 19950616
AT 168697 E 19980815 AT 1995-923397 19950616
ES 2119454 T3 19981001 ES 1995-923397 19950616
ZA 9505052 A 19960209 ZA 1995-5052 19950616
US 5716936 A 19980210 US 1996-750653 19961218
PRAI FR 1994-7540 A 19940620
WO 1995-FR796 W 19950616
OS MARPAT 124:260823
IT 175153-95-4P 175153-96-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidine derivs. as cholecystokinin and gastrin receptor ligands)

RN 175153-95-4 CAPLUS
CN Proline, 1-[[[(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-, 2-(1,1-dimethylethyl) ester, (2α,4β,5α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 175153-96-5 CAPLUS
CN Prolinamide, N-[[[(3-carboxyphenyl)amino]carbonyl]glycyl]-N-(3,3-dimethylbutyl)-5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-, (2α,4β,5α)- (9CI) (CA INDEX NAME)


Relative stereochemistry.

Page 70

JP2004_018717_2.trn

CN Prolinamide, N-[[[(3-(phenylmethoxy)carbonyl)phenyl]amino]carbonyl]glycyl]-N-(3,3-dimethylbutyl)-5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-, (2α,4β,5α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1994:217658 CAPLUS
DN 120:217658
TI Preparation and formulation of 2-aryl-3-(ureidoacetyl)thiazolidine-4-carboxylates and analogs as CCK receptor and gastrin receptor ligands
IN Capet, Marc; Cotrel, Claude; Guyon, Claude; Joannic, Michel; Manfre, Franco; Roussel, Gerard; Dubroeuq, Marie Christine; Cheve, Michel; Dutruc-Rosset, Gilles
PA Rhone-Poulenc Rorer SA, Fr.
SO PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 9301167 A1 19930121 WO 1992-FR626 19920703
W: AU, CA, CS, FI, HU, JP, KR, NO, PL, RU, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE
FR 2678938 A1 19930115 FR 1991-8675 19910710
FR 2678938 B1 19931008
EP 527069 A1 19930210 EP 1992-401904 19920703
R: PT
AU 9223275 A1 19930211 AU 1992-23275 19920703
AU 662345 B2 19950831
EP 593639 A1 19940427 EP 1992-915456 19920703
EP 593639 B1 19950405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
JP 06509331 T2 19941020 JP 1992-502018 19920703
JP 3034043 B2 20000417
AT 120732 E 19950415 AT 1992-915456 19920703

ES 2071510	T3	19950616	ES 1992-915456	19920703
HU 70403	A2	19951030	HU 1994-61	19920703
PL 171054	B1	19970228	PL 1992-313380	19920703
PL 171094	B1	19970328	PL 1992-313379	19920703
PL 171112	B1	19970328	PL 1992-313381	19920703
PL 171095	B1	19970328	PL 1992-313382	19920703
PL 171333	B1	19970430	PL 1992-302029	19920703
CZ 283602	B6	19980513	CZ 1994-49	19920703
RU 2118316	C1	19980827	RU 1994-15258	19920703
CA 2102697	C	20030930	CA 1992-2102697	19920703
ZA 9205128	A	19930428	ZA 1992-5128	19920709
NO 9304300	A	19931126	NO 1993-4300	19931126
NO 180166	B	19961118		
NO 180166	C	19970226		
FI 105190	B1	20000630	FI 1994-72	19940107
US 5610144	A	19970311	US 1994-175381	19940627
PRAI FR 1991-8675	A	19910710		
WO 1992-ER626	A	19920703		

OS MARPAT 120:217658

IT 153242-87-6P 153243-31-3P 153243-32-4P

153244-03-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of CCK and gastrin receptor ligand)

RN 153242-87-6 CAPLUS

CN 4-Thiazolidinecarboxylic acid, 2-(3-pyridinyl)-3-[[[3-[[2-(trimethylsilyl)ethoxy]carbonyl]phenyl]amino]carbonyl]amino]acetyl]-, 1,1-dimethylethyl ester, (2R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153243-31-3 CAPLUS

CN L-Proline, 5-(1H-indol-3-yl)-1-[N-[[[3-[[2-(trimethylsilyl)ethoxy]carbonyl]phenyl]amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153243-32-4 CAPLUS

CN L-Proline, 5-(1H-indol-3-yl)-1-[N-[[[3-[[2-(trimethylsilyl)ethoxy]carbonyl]phenyl]amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153244-03-2 CAPLUS

CN D-Proline, N-[[[3-[[phenylmethoxy]carbonyl]phenyl]amino]carbonyl]glycyl]-5-(2-pyridinyl)-, 1,1-dimethylethyl ester, (5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 153241-68-0P 153241-76-0P 153241-77-1P


153241-89-5P 153241-90-8P 153242-19-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as CCK and gastrin receptor ligand)

RN 153241-68-0 CAPLUS

CN 4-Thiazolidinecarboxylic acid, 3-[[[3-(3-carboxyphenyl)amino]carbonyl]amino]acetyl]-2-(3-pyridinyl)-, 4-(1,1-dimethylethyl) ester, (2R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153241-76-0 CAPLUS

CN Quinoline, 1,2,3,4-tetrahydro-1-[[1-[[[3-(3-methylphenyl)amino]carbonyl]amino]acetyl]-5-phenyl-2-pyrrolidinyl]carbonyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 153241-77-1 CAPLUS

CN Piperidine, 3,3-dimethyl-1-[[1-[[[3-(3-methylphenyl)amino]carbonyl]amino]acetyl]-5-phenyl-2-pyrrolidinyl]carbonyl]-, cis- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 153241-89-5 CAPLUS

CN L-Proline, 1-[N-[[[3-(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(1H-indol-3-yl)-, 2-(1,1-dimethylethyl) ester, cis- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153241-90-8 CAPLUS

CN L-Proline, 1-[N-[[[3-(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(1H-indol-3-yl)-, 2-(1,1-dimethylethyl) ester, trans- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153242-19-4 CAPLUS

CN D-Proline, N-[[[(3-carboxyphenyl)amino]carbonyl]glycyl-5-(2-pyridinyl)-, 2-(1,1-dimethylethyl) ester, (5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1992:256054 CAPLUS

DN 116:256054

TI Preparation of peptide-linked 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles and related compounds as inhibitors of cholecystokinin and gastrin

IN Molino, Bruce F.; Darkes, Paul R.; Ewing, William R.

PA Rorer International (Holdings), Inc., USA

SO PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9200295	A1	19920109	WO 1991-US4236	19910613
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	US 5162336	A	19921110	US 1990-573514	19900824
	CA 2068887	AA	19911222	CA 1991-2068887	19910613
	AU 9186116	A1	19920123	AU 1991-86116	19910613
	AU 640277	B2	19930819		
	EP 491943	A1	19920701	EP 1991-916717	19910613
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
PRAI	US 1990-542495	A	19900621		
	US 1990-573514	A2	19900824		
	WO 1991-US4236	A	19910613		

OS MARPAT 116:256054

IT 139985-57-2P 139985-59-4P 139985-60-7P


139986-26-8P 139986-28-0P 140148-72-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of, as cholecystokinin and gastrin antagonist)


RN 139985-57-2 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[1-[[2-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 139986-26-8 CAPLUS

CN L-Proline, 1-[[1-[[2-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-L-prolyl]- (R)- (9CI) (CA INDEX NAME)




RN 139986-28-0 CAPLUS

CN 3,4-Pyrrolidinedicarboxylic acid, 1-[[1-[[2-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 139985-59-4 CAPLUS


CN 3-Pyrrolidinedicarboxylic acid, 1-[[1-[[2-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]-, [3S-[3R*(R*(S*))]]- (9CI) (CA INDEX NAME)



RN 139985-60-7 CAPLUS


CN 2-Pyrrolidineacetic acid, 1-[[1-[[2-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]-, [3R-[3R*(S*(S*))]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 140148-72-7 CAPLUS

CN 3-Pyrrolidinedicarboxylic acid, 1-[[1-[[2-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]-, [3R-[3R*(S*(R*))]]- (9CI) (CA INDEX NAME)




IT 139986-02-0P 139986-13-3P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of, as intermediate for peptide-linked tetrahydropyridindole cholecystokinin and gastrin antagonist)

RN 139986-02-0 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[[1-[[2-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 139986-13-3 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 1-[[1-[[2-[[3,4-dichlorophenyl]amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]-, phenylmethyl ester, [3R-[3R*[S*(S*)]]]- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1988:570130 CAPLUS
DN 109:170130
TI Preparation and formulation of novel mitomycin derivatives as antitumor agents
IN Muto, Kenji; Kuroda, Tokuyuki; Morimoto, Makoto
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO Japan Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63035575	A2	19880216	JP 1986-181012	19860731
PRAI JP 1986-181012		19860731		
OS MARPAT 109:170130				
IT 116939-80-1P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study, unclassified);

Page 81

JP2004_018717_2.trn




RN 103126-82-5 CAPLUS
CN L-Proline, 1-[[1-[[N-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]-, compound with L-arginine (9CI) (CA INDEX NAME)

CM 1

CRN 103126-81-4
CMF C20 H26 N4 O5


Absolute stereochemistry.



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2


Absolute stereochemistry.



-> LOG Y
COST IN JAPANESE YEN

SINCE FILE ENTRY TOTAL
SESSION

study); PREP (Preparation)
(preparation of, as antitumor agent)
RN 116939-80-1 CAPLUS
CN Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[[aminocarbonyl]oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-1-[[1-[[N-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]-, (1aS-1a,8β,8a,8b)]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1986:443340 CAPLUS
DN 105:43340
TI Tripeptide derivatives for use as antihypertensive agents
IN Eguchi, Chikahiko; Kurauchi, Masahiko; Sakakibara, Shumpei
PA Ajinomoto Co., Inc., Japan
SO Eur. Pat. Appl., 47 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 173510	A2	19860305	EP 1985-305727	19850813
EP 173510	A3	19870916		
R: CH, DE, FR, GB, IT, LI				
JP 61053298	A2	19860317	JP 1984-176355	19840824
JP 06055758	B4	19940727		
US 4719200	A	19880112	US 1985-769029	19850826
PRAI JP 1984-176355	A	19840824		
IT 103126-81-4P 103126-82-5P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of, as antihypertensive)				
RN 103126-81-4 CAPLUS				
CN L-Proline, 1-[[1-[[N-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]-, (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

Page 82

JP2004_018717_2.trn

FULL ESTIMATED COST 5895 5996
STN INTERNATIONAL LOGOFF AT 11:05:17 ON 09 FEB 2005

Host Name: +++
OK
OK

W = -N- 2" テット化化合物
R²

Dialing COMPUERVE at 0070670488888

OK

CONNECT 45333

Connecting through CompuServe

0019TEA

Host Name: STNT

Connected to 0004 CAA_0

Welcome to STN International! Enter x:x
LOGINID:TKYBAJ74
PASSWORD:


TERMINAL (ENTER 1, 2, 3, EUC, SJIS OR ?):2

***** Welcome to STN International *****

Item	Date	Headline
NEWS 1		STN, CAS FILES Workshop Schedule in Japan
NEWS 2	Oct 26	KOREAPAT now available on STN
NEWS 3	Nov 19	Current-awareness alerts, saved answer sets, and current search transcripts to be affected by CERAS, COMPUAB, ELCOM, and SOLIDSTATE reloads
NEWS 4	Nov 22	November 22, 2004 LISA new on STN
NEWS 5	Dec 1	PHAR reloaded with additional data
NEWS 6	Dec 15	12 databases to be removed from STN on 31, Dec., 2004
NEWS 7	Dec 17	MEDLINE update schedule for December 2004
NEWS 8	Dec 20	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 9	Dec 20	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 10	Dec 20	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 11	Dec 20	CERAS reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS 12	Dec 20	Three new fields added to IFIPAT/IFIUDS/IFICDB
NEWS 13	Dec 27	EPFULL: New patent full text database to be available on STN
NEWS 14	Dec 31	CAPLUS - PATENT COVERAGE EXPANDED
NEWS 15	Jan 1	No connect-hour charges in EPFULL during January and February 2005
NEWS 16	Jan 5	Urgent announcement to STN customers accessing via phone line WorldCom access points were changed
NEWS 17	Jan 12	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS HOURS		STN operating Hours
NEWS WORLDCOM		STN High Speed Access via Worldcom
NEWS INTER		INTERNET ACCESS to STNT(STN-Tokyo)

Page 1


JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):348

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[3-methylphenyl]amino]carbonyl]-(2-methylpropyl)amino]acetyl]- (9CI)
MF C26 H33 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[ethyl]-(4-ethylphenyl)amino]carbonyl]amino]acetyl]- (9CI)
MF C25 H31 N5 O3

NEWS EXPRESS STN Express 7.0 with Discover!
(Windows) Now available!
NEWS WWW STN Tokyo World Wide Web Site

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:59:13 ON 08 FEB 2005

-> FILE REG COS=4PRD
COST IN JAPANESE YEN

SINCE FILE	TOTAL
ENTRY	SESSION
36	36

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:59:35 ON 08 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)
CHARGED TO COST=4PRD

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-7
DICTIONARY FILE UPDATES: 6 FEB 2005 HIGHEST RN 826990-02-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

-> ACT RD018717/A

L1 STR
L2 STR
L3


-> D SCAN

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[[25]-2-[[[3,5-dichlorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C34 H43 Cl2 N7 O4

Absolute stereochemistry.


Page 2

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[2-[[[2,4-difluorophenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
MF C22 H24 F5 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-bromophenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI)
MF C28 H34 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[25]-3-methyl-2-[[[2-methylphenyl]amino]carbonyl]amino]-1-oxobutyl]- (9CI)
MF C25 H31 N5 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-((1H-benzimidazol-2-yl)-1-oxo-3-((4-methylphenyl)amino)propyl)-1-oxopropyl- (9CI)
 MF C27 H35 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 3-Piperidinecarboxylic acid, 1-[[1-[[2-[[3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl-, phenylmethyl ester (9CI)
 MF C37 H37 Cl2 N5 O5



Page 5


JP2004_018717_2.trn

MF C24 H29 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperazine, 1-[2-[[[3-methoxyphenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 MF C23 H28 F3 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-((1H-benzimidazol-2-yl)-1-oxo-3-((cyclohexyl)amino)propyl)-1-oxopropyl- (9CI)
 MF C30 H39 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-((1H-benzimidazol-2-yl)-1-oxo-3-((3-chlorophenyl)amino)propyl)-1-oxopropyl- (9CI)
 MF C30 H32 Cl N5 O2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[[2S]-2-[[[(2,6-dichloro-4-pyridinyl)amino]carbonyl]amino]-4-[[1,4-dihydro-2-oxo-3(2H)-quinazolinyl]-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
 MF C33 H42 Cl2 N8 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-((2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[2-methylpropyl]amino]carbonyl)amino]acetyl]- (9CI)
 MF C26 H30 F3 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-((2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[ethyl]amino]carbonyl)amino]acetyl]- (9CI)

Page 6

JP2004_018717_2.trn


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-((1H-benzimidazol-2-yl)-1-[[3-[[2,4-dichlorophenyl)amino]carbonyl]amino] (2-methylpropyl)amino)-1-oxopropyl]- (9CI)
 MF C26 H31 Cl2 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 4-Thiazolidinecarboxylic acid, 3-[[[3-(3-carboxyphenyl)amino]carbonyl]amino]acetyl]-2-(3-pyridinyl)-, 4-((1,1-dimethylethyl) ester, (2R-cis)- (9CI)
 MF C23 H26 N4 O6 S


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2-chlorophenyl)amino]carbonyl]amino]-4-
 [4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]-
 (9CI)
 MF C34 H44 Cl N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[(2,4-dichlorophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-
 (9CI)
 MF C25 H29 Cl2 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[(2,3-dichlorophenyl)amino]carbonyl]propylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C24 H27 Cl2 N5 O3


Page 9

JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(2-methoxyphenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI)
 MF C27 H35 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN D-Proline, N-[[[(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(2-pyridinyl)-, 2-(1,1-dimethylethyl) ester, (5S)-rel- (9CI)
 MF C24 H28 N4 O6


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[4-(4-ethylphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]- (9CI)
 MF C22 H25 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(4-methoxyphenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C29 H37 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(4-bromophenyl)amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
 MF C30 H32 Br N5 O2

Page 10

JP2004_018717_2.trn


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(3-fluorophenyl)amino]carbonyl]amino]-1,4-dioxobutyl]-
 (9CI)
 MF C34 H44 F N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(4-ethylphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]- (9CI)
 MF C27 H35 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(2-methoxyphenyl)amino]carbonyl]propylamino]acetyl]- (9CI)
 MF C25 H31 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[methyl[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]acetyl]- (9CI)
 MF C23 H24 F3 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[3-chlorophenyl]amino]carbonyl](1-methylethyl)amino]-1-oxopropyl]- (9CI)
 MF C25 H29 Cl N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[2-methylphenyl]amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
 MF C31 H35 N5 O2



Page 13


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Benzoic acid, 4-[[[[(1S)-1-[[[1,4'-bipiperidin]-1'-yl]carbonyl]-3-{4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-3-oxopropyl]amino]carbonyl]amino]-, ethyl ester (9CI)
 MF C37 H49 N7 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(2-methylphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]- (9CI)
 MF C26 H33 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[butyl[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C26 H30 F3 N5 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[2-methylpropyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C27 H32 F3 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Proline, 1-[N-[[[3-carboxyphenyl]amino]carbonyl]glycyl]-5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-, 2-(1,1-dimethylethyl) ester, (2α,4β,5α)- (9CI)
 MF C29 H35 F N4 O9 S

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Page 14




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[[(2,4-dichlorophenyl)amino]carbonyl]methylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C22 H23 Cl2 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[[(2,4-dichlorophenyl)amino]carbonyl](1-methylethyl)amino]-1-oxopropyl]- (9CI)
 MF C25 H28 Cl2 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[[(2,4-dichlorophenyl)amino]carbonyl](1-methylethyl)amino]-1-oxopropyl]- (9CI)
 MF C25 H29 Cl2 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-((1H-benzimidazol-2-yl)-1-[3-(((4-nitrophenyl)amino)carbonyl)propylamino]-1-oxopropyl)- (9CI)
MF C25 H30 N6 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN D-Proline, N-(((3-carboxyphenyl)amino)carbonyl)glycyl-5-phenyl-4-(1-pyrrolidinylcarbonyl)-, 2-(1,1-dimethylethyl) ester, (4S,5S)-rel- (9CI)
MF C30 H36 N4 O7

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-((2S)-2-(((4-chloro-2-(trifluoromethyl)phenyl)amino)carbonyl)amino)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-


Page 17

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-(((2-bromophenyl)amino)carbonyl)butylamino)acetyl)-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C25 H30 Br N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-(((3-ethylphenyl)amino)carbonyl)methylamino)acetyl)- (9CI)
MF C24 H29 N5 O3



piperidiny]-1,4-dioxobutyl)- (9CI)
MF C35 H43 Cl F3 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-((2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidiny]-1,4-dioxo-2-(((2,4,5-trimethylphenyl)amino)carbonyl)amino)butyl)- (9CI)
MF C37 H51 N7 O4


Absolute stereochemistry.

Page 18

JP2004_018717_2.trn


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[3-(((1-methylethyl)amino)carbonyl)amino)-1-oxopropyl)- (9CI)
MF C26 H32 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[3-(cyclohexylamino)carbonyl)amino)-1-oxopropyl)- (9CI)
MF C29 H36 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(((3-cyanophenyl)amino)carbonyl)propylamino)-1-oxopropyl)- (9CI)
MF C26 H30 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-[(1H-benzimidazol-2-yl)-1-[[3-(3-methylphenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C27 H35 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chloro-4-fluorophenyl)amino]carbonyl]amino]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
 MF C34 H43 Cl F N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(1,1'-biphenyl)-4-ylamino]carbonyl]amino]-


Page 21

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-[(2-benzoxazolyl)-1-[[3-(butyl[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C27 H31 F3 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-[(2-benzoxazolyl)-1-[[3-[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI)
 MF C34 H46 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-[(1H-benzimidazol-2-yl)-1-[[3-[[[4-methoxyphenyl]amino]carbonyl]propylamino]-1-oxopropyl]- (9CI)
 MF C26 H33 N5 O3

JP2004_018717_2.trn

4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]
 (9CI)


MF C40 H49 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]butylamino]acetyl]-4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C31 H43 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-[(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[methyl[[2-methylphenyl]amino]carbonyl]amino]acetyl]- (9CI)
 MF C23 H27 N5 O3


Page 22

JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-[(1H-benzimidazol-2-yl)-1-[[3-(butyl[[2,3-dichlorophenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C26 H31 Cl2 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[2-(trifluoromethoxy)phenyl]amino]carbonyl]amino]butyl]- (9CI)
 MF C35 H44 F3 N7 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(3-methoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
MF C35 H47 N7 O5

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[butyl[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]acetyl]- (9CI)

Page 25


JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-2-[[[(3-bromophenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI)
MF C24 H28 Br N5 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(3-butyl[[[4-methoxyphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C27 H35 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1)-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C28 H37 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[(ethyl[[[2-fluorophenyl]amino]carbonyl]amino]acetyl)- (9CI)
MF C23 H26 F N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[(3-butyl[[[4-(methylthio)phenyl]amino]carbonyl]amino]-1-oxopropyl)- (9CI)
MF C27 H34 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(3-(cyclohexyl[[[3,4-dichlorophenyl]amino]carbonyl]amino]-1-oxopropyl)- (9CI)
MF C28 H33 Cl2 N5 O2

Page 26

JP2004_018717_2.trn

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-2-[[[4-(4,6-dimethyl-2-pyrimidinyl)-1-piperazinyl]carbonyl]-4-hydroxy-, (2R,4R)- (9CI)
MF C22 H27 Cl N6 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,4-difluorophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C34 H43 F2 N7 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[(2-methylpropyl)((phenylamino)carbonyl)amino]acetyl]- (9CI)
MF C25 H31 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]ethylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C29 H39 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[2-[[[3-bromophenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
MF C22 H25 Br F3 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(cyclohexyl[(2-fluorophenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Piperidinecarboxylic acid, 1-[[1-[(2-[[[3,4-dichlorophenyl]amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]- (9CI)
MF C30 H31 Cl2 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[2,4-dichlorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C34 H43 Cl2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


MF C28 H34 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-2-[[[2,6-dimethylphenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI)
MF C26 H33 N5 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-chlorophenyl]amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI)
MF C26 H32 Cl N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 4-[[[2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-2-oxoethyl](2-methylpropyl)amino]carbonyl]amino]-, ethyl ester (9CI)
MF C28 H35 N5 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[(ethyl[(2-methoxyphenyl)amino]carbonyl]amino]acetyl]- (9CI)
MF C24 H29 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[2-[[[2,6-dimethylphenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
MF C24 H30 F3 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-cyanophenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI)
MF C29 H34 N6 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[4-methoxyphenyl]amino]carbonyl](1-methylethylamino)-1-oxopropyl]- (9CI)
MF C26 H33 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[2-bromophenyl]amino]carbonyl](2-methylpropylamino)-1-oxopropyl]- (9CI)
MF C26 H32 Br N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN L-Proline, 1-[1-[[2-[[[3,4-dichlorophenyl]amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-L-prolyl]-, (R)- (9CI)
MF C29 H29 Cl2 N5 O5


Page 33

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 4-[[[2-[[2-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-2-oxoethyl]propylamino]carbonyl]amino]-, ethyl ester (9CI)
MF C27 H33 N5 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[3-methyl-2-[[[2-(2-methylphenyl)amino]carbonyl]amino]-1-oxobutyl]-4-[3-[[trifluoromethyl]-2-pyridinyl]- (9CI)
MF C23 H28 F3 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[cyclohexyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C30 H39 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[[2S]-2-[[[2-chloro-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C35 H43 Cl F3 N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[3-bromophenyl]amino]carbonyl](2-methylpropylamino)acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C25 H30 Br N5 O3


Page 34

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-methylphenyl]amino]carbonyl](1-phenylethylamino)-1-oxopropyl]- (9CI)
MF C31 H35 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[4-ethoxyphenyl]amino]carbonyl](2-methylpropylamino)-1-oxopropyl]- (9CI)
MF C28 H37 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 3,3-dimethyl-1-[[1-[[[3-methylphenyl]amino]carbonyl]amino]acetyl]-5-phenyl-2-pyrrolidinyl]carbonyl]-, cis- (9CI)
MF C28 H36 N4 O3


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2,5-dimethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
MF C36 H49 N7 O6

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[[(2,4-dimethoxyphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]- (9CI)
MF C27 H35 N5 O5


Page 37

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(4-ethoxyphenyl)amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
MF C32 H37 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(4-methoxyphenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI)
MF C27 H35 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN L-Proline, 5-(1H-indol-3-yl)-1-[N-[[[3-[[2-(trimethylsilyl)ethoxy]carbonyl]phenyl]amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, cis- (9CI)
MF C32 H42 N4 O6 Si


Absolute stereochemistry.

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[(2,6-bis(1-methylethyl)phenyl)amino]carbonyl]propylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C30 H41 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 4-[[[2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-2-oxoethyl]methylamino]carbonyl]amino]-, ethyl ester (9CI)
MF C25 H29 N5 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(cyclohexyl[(2-methylphenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C29 H37 N5 O2

Page 38


JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[[(2S)-2-[[[(4-bromophenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C34 H44 Br N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(2-methoxyphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]- (9CI)
MF C26 H33 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[4-(methylthio)phenyl]amino]carbonyl]propylamino]acetyl]- (9CI)
 MF C25 H31 N5 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[4-(2-bromophenyl)amino]carbonyl]methylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C22 H24 Br N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[2-bromophenyl]amino]carbonyl] (1-methylethyl)amino]-1-oxopropyl]- (9CI)
 MF C25 H29 Br N4 O3



Page 41


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[2-bromophenyl]amino]carbonyl] (1-methylethyl)amino]-1-oxopropyl]- (9CI)
 MF C25 H30 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[1-oxo-3-(propyl[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]propyl]- (9CI)
 MF C26 H30 F3 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Proline, 5-(2-fluorophenyl)-4-(4-morpholinylsulfonyl)-1-(N-[[[3-(phenylmethoxy)carbonyl]phenyl]amino]carbonyl]glycyl)-, 1,1-dimethylethyl ester, (2α,4β,5α)- (9CI)
 MF C36 H41 F N4 O9 S

Relative stereochemistry.


Page 42



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2,4-dimethylphenyl]amino]carbonyl]amino]-1,4'-dioxobutyl]- (9CI)
 MF C36 H49 N7 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 2-Azetidinecarboxylic acid, 3-[[[1-(aminoiminomethyl)-3-piperidinyl]methyl]-4-oxo-1-[[4-[[[phenylamino]carbonyl]amino]acetyl]-1-piperazinyl]carbonyl]- (2S,3R)- (9CI)
 MF C25 H34 N8 O6

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 3-[[[butyl] [[4-nitrophenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C25 H30 N6 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[2,4-dimethoxyphenyl]amino]carbonyl]methylamino]acetyl]- (9CI)
 MF C24 H29 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[4-ethylphenyl]amino]carbonyl] (1-methylethyl)amino]-1-oxopropyl]- (9CI)

MF C27 H34 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-(3-(cyclohexylamino)propyl)- (9CI)
 MF C28 H32 Cl2 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-((2-bromophenyl)amino)carbonylpropylamino)-1-oxopropyl)- (9CI)
 MF C25 H30 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Cyclopropanecarboxylic acid, 3-methyl-N-((phenylamino)carbonyl)-L-valyl-

Page 45

JP2004_018717_2.trn


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-((2S)-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-2-(((2-methylphenyl)amino)carbonyl)amino)-1,4-dioxobutyl)- (9CI)
 MF C35 H47 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-(((4-bromophenyl)amino)carbonyl)butylamino)acetyl)-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C25 H30 Br N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-(((2-methoxyphenyl)amino)carbonyl)methylamino)acetyl)- (9CI)
 MF C23 H27 N5 O4

(4R)-4-((7-methoxy-2-phenyl-4-quinolinyl)oxy)-L-prolyl-1-amino-2-ethenyl-, (1R,2S)- (9CI)
 MF C40 H43 N5 O7

Absolute stereochemistry.




2002-522554

C型肝炎个比较

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-((2S)-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-2-(((4-ethylphenyl)amino)carbonyl)amino)-1,4-dioxobutyl)- (9CI)
 MF C36 H49 N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Page 46


JP2004_018717_2.trn

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-(3-(butyl((4-chlorophenyl)amino)carbonyl)amino)-1-oxopropyl)- (9CI)
 MF C26 H31 Cl N4 O3

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT




L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-(3-(((3-bromophenyl)amino)carbonyl)cyclohexylamino)-1-oxopropyl)- (9CI)
 MF C28 H33 Br N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-(((2,6-dimethylphenyl)amino)carbonyl)propylamino)-1-oxopropyl)- (9CI)
 MF C27 H35 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[3-(butyl[(4-nitrophenyl)amino]carbonyl)amino]-1-oxopropyl]]- (9CI)
MF C26 H32 N6 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(5-fluoro-2-methylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]]- (9CI)
MF C35 H46 F N7 O4


Absolute stereochemistry.

(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C27 H35 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[ethyl[(3-methylphenyl)amino]carbonyl]amino]acetyl]- (9CI)
MF C24 H29 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[3-(butyl[(2,4-dichlorophenyl)amino]carbonyl)amino]-1-oxopropyl]- (9CI)
MF C26 H30 Cl2 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[3-(cyclohexyl[(3-methoxyphenyl)amino]carbonyl)amino]-1-oxopropyl]- (9CI)
MF C29 H36 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-acetylphenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]]- (9CI)
MF C36 H47 N7 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[butyl[(2,6-dimethylphenyl)amino]carbonyl]amino]acetyl]-4-



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-3-methyl-1-oxo-2-[[[(phenylamino)carbonyl]amino]butyl]]- (9CI)
MF C24 H29 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(butyl[(2,4-dimethoxyphenyl)amino]carbonyl)amino]-1-oxopropyl]- (9CI)
MF C28 H37 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-4-hydroxy-2-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl]-, (2R,4R)- (9CI)

MF C21 H24 Cl N5 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
 MF C35 H43 Cl F3 N7 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[butyl[[3-methoxyphenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C26 H33 N5 O4


Page 53



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-2-[[[2,4-difluorophenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI)
 MF C24 H27 F2 N5 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-butyl[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C27 H32 F3 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN L-Proline, 1-[1-[N-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]- (9CI)
 MF C20 H26 N4 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[[2-bromophenyl]amino]carbonyl]ethylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C23 H26 Br N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-butyl[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C27 H31 F3 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-chlorophenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI)
 MF C28 H34 Cl N5 O2

Page 54

CI COM


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[3,4-dimethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
 MF C36 H49 N7 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[(2-methylpropyl)[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]acetyl]- (9CI)

MF C26 H30 F3 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[2,6-dimethylphenyl]amino]carbonyl]ethylamino]acetyl]- (9CI)
 MF C25 H31 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperazine, 1-[2-[[[2,4-dichlorophenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 MF C22 H24 Cl2 F3 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[2-bromophenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI)
 MF C28 H34 Br N5 O2

2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]-, [3R-[3R-[S*(S*)]]]- (9CI)
 MF C30 H31 Cl2 N5 O5


Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[[2S]-2-[[[2,6-difluorophenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
 MF C34 H43 F2 N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[2S]-2-[[[4-methoxyphenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI)
 MF C25 H31 N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-methylphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C27 H35 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 2-Pyrrolidineacetic acid, 1-[[1-[[2-[[[3,4-dichlorophenyl]amino]carbonyl]-

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[3-fluorophenyl]amino]carbonyl]amino]acetyl]- (9CI)
 MF C25 H30 F N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[ethyl[[[4-(methylthio)phenyl]amino]carbonyl]amino]acetyl]- (9CI)
 MF C24 H29 N5 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperazine, 1-[2-[[[2-methoxyphenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 MF C23 H28 F3 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI)
 MF C34 H47 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-[(1H-benzimidazol-2-yl)-1-[[1-oxo-3-[(phenylamino)carbonyl](1-phenylethyl)amino]propyl]- (9CI)
MF C30 H33 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-[(1H-benzimidazol-2-yl)-1-[[3-[[[3-cyanophenyl]amino]carbonyl][2-methylpropyl]amino]-1-oxopropyl]- (9CI)
MF C27 H32 N6 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Pyrrolidinecarboxylic acid, 1-[[1-[[2-[[[3,4-dichlorophenyl]amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]-, [3R-[3R*[5*(R*)]]]- (9CI)
MF C29 H29 Cl2 N5 O5

Page 61


JP2004_018717_2.trn

IN Piperidine, 1-[[[[(2,3-dichlorophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C25 H29 Cl2 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[[(4-bromophenyl)amino]carbonyl]propylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C24 H28 Br N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[[(4-chlorophenyl)amino]carbonyl]methylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C22 H24 Cl N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-[(1H-benzimidazol-2-yl)-1-[[3-[[cyclohexyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C29 H37 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[[25]-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-2-[[[2-fluorophenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
MF C34 H44 F N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN


Page 62

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-[(1H-benzimidazol-2-yl)-1-[[3-[[[3-bromophenyl]amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
MF C30 H32 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-[(1H-benzimidazol-2-yl)-1-[[3-[[[4-(1-methylethyl)phenyl]amino]carbonyl][2-methylpropyl]amino]-1-oxopropyl]- (9CI)
MF C29 H39 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN L-Proline, 1-[N-[[[3-carboxyphenyl]amino]carbonyl]glycyl]-5-(1H-indol-3-yl)-, 2-[[1,1-dimethylethyl] ester, trans- (9CI)
MF C27 H30 N4 O6


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-bromophenyl)amino]carbonyl]amino]-4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny)]-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C34 H44 Br N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(4-ethoxyphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]- (9CI)
MF C27 H35 N5 O4


Page 65

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(4-methoxyphenyl)amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
MF C31 H35 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(2-methylphenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI)
MF C27 H35 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN D-Proline, N-[[[3-[(phenylmethoxy)carbonyl]phenyl]amino]carbonyl]glycyl-5-(2-pyridinyl)-, 1,1-dimethylethyl ester, (5S)-rel- (9CI)
MF C31 H34 N4 O6

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(4-(1-methylethyl)phenyl)amino]carbonyl]propylamino]acetyl]- (9CI)
MF C27 H35 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(3-fluorophenyl)amino]carbonyl]methylamino]acetyl]- (9CI)
MF C22 H24 F N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[(4-chlorophenyl)amino]carbonyl](1-methylethyl)amino]-1-oxopropyl]- (9CI)
MF C25 H29 Cl N4 O3

Page 66


JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny)]-1-piperidinyl]-2-[[[(4-methoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
MF C35 H47 N7 O5


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(2-methylpropyl)[[(4-(methylthio)phenyl)amino]carbonyl]amino]acetyl]- (9CI)

MF C26 H33 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[butyl[[[4-chlorophenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)]- (9CI)
 MF C25 H30 Cl N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[2,3-dichlorophenyl]amino]carbonyl]methylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)]- (9CI)
 MF C22 H23 Cl2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[[[2,3-dichlorophenyl]amino]carbonyl]methylamino]acetyl]-1-oxopropyl]- (9CI)
 MF C25 H28 Cl2 N4 O3


JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[5-chloro-2-methoxyphenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
 MF C35 H46 Cl N7 O5

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[2-phenoxyphenyl]amino]carbonyl]amino]butyl]-



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[[4-bromophenyl]amino]carbonyl]methylamino]acetyl]-1-oxopropyl]- (9CI)
 MF C25 H30 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[[4-methylphenyl]amino]carbonyl]propylamino]-1-oxopropyl]- (9CI)
 MF C26 H33 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Benzoic acid, 3-[[[2-[[[3,3-dimethyl-1-piperidinyl]carbonyl]-2-(2-fluorophenyl)-3-(phenylsulfonyl)-1-pyrrolidinyl]-2-oxoethyl]amino]carbonyl]amino]-, (2α,3β,5α)- (9CI)
 MF C34 H37 F N4 O7 S

Relative stereochemistry.

JP2004_018717_2.trn


(9CI)
 MF C40 H49 N7 O5

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[butyl[[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)]- (9CI)
 MF C26 H30 F3 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[4-ethoxyphenyl]amino]carbonyl]methylamino]acetyl]- (9CI)
 MF C24 H29 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[4-methoxyphenyl]amino]carbonyl](1-methylethyl)amino]-1-oxopropyl]- (9CI)
 MF C26 H32 N4 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-(cyclohexyl[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino)-1-oxopropyl]- (9CI)
 MF C29 H33 F3 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzimidazol-2-yl)-1-[3-[[[4-bromophenyl]amino]carbonyl]propylamino]-1-oxopropyl]- (9CI)
 MF C25 H30 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


Page 73

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[butyl[[[2,4-dichlorophenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)]- (9CI)
 MF C25 H29 Cl2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[methyl[[[4-(methylthio)phenyl]amino]carbonyl]amino]acetyl]- (9CI)
 MF C23 H27 N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[butyl[[[3-


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[butyl[[[4-chlorophenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C26 H32 Cl N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chloro-2-methylphenyl)amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
 MF C35 H46 Cl N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[phenylamino]carbonyl]amino]butyl]- (9CI)
 MF C34 H45 N7 O4

Absolute stereochemistry.

Page 74


JP2004_018717_2.trn

chlorophenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C26 H31 Cl N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-(cyclohexyl[[[2,4-difluorophenyl]amino]carbonyl]amino)-1-oxopropyl]- (9CI)
 MF C28 H32 F2 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[4-(1-methylethyl)phenyl]amino]carbonyl]propylamino]-1-oxopropyl]- (9CI)
 MF C28 H37 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-bromophenyl]amino]carbonyl]butylamino]-1-oxopropyl]- (9CI)
 MF C26 H32 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(1,1'-biphenyl)-2-ylamino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C40 H49 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2-methoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
MF C35 H47 N7 O5


Absolute stereochemistry.

Page 77

JP2004_018717_2.trn


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[[3-[[butyl[[4-methoxyphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C27 H34 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[[3-[[cyclohexyl[[2-methylphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C29 H36 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(18-benzimidazol-2-yl)-1-[(2S)-2-[[[(2-bromophenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI)
MF C24 H28 Br N5 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[butyl[[4-ethylphenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C27 H35 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 4-[[[2-[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]-2-oxoethyl]ethylamino]carbonyl]amino]-, ethyl ester (9CI)
MF C26 H31 N5 O5




Page 78

JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(18-benzimidazol-2-yl)-1-[[3-[[butyl[[3-methoxyphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C27 H35 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-2-[[4-(4-ethyl-1-piperazinyl)-1-piperidinyl]carbonyl]-4-hydroxy-, (2R,4R)- (9CI)
MF C23 H34 Cl N5 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2,4-dimethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
 MF C36 H49 N7 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[(4-chlorophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C25 H30 Cl N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[(4-bromophenyl)amino]carbonyl]ethylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C23 H26 Br N5 O3

Page 81




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[(2-methylpropyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C26 H33 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-1-[1-[N-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]-, [1a5-(1aα,8β,8aα,8bα)]- (9CI)
 MF C30 H35 N7 O8




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperazine, 1-[2-[[[(3-fluorophenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 MF C22 H25 F4 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(cyclohexyl[[4-methylphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C29 H37 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-2-[[[(2,4-dimethoxyphenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI)
 MF C26 H33 N5 O4

Absolute stereochemistry.


Page 82



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2,4-dimethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
 MF C35 H44 F3 N7 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(4-methylphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]- (9CI)
 MF C26 H33 N5 O3

A63-35575
 抗肿瘤




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[ethyl[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]acetyl]- (9CI)
MF C26 H33 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-(2-[[[2,4-dimethoxyphenyl]amino]carbonyl]amino)-3-methyl-1-oxobutyl)-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
MF C24 H30 F3 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[4-bromophenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI)
MF C28 H34 Br N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-methoxyphenyl]amino]carbonyl]-(1-methylethyl)amino]-1-oxopropyl]- (9CI)
MF C26 H33 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-fluorophenyl]amino]carbonyl]-(2-methylpropyl)amino]-1-oxopropyl]- (9CI)
MF C26 H32 F N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Pyrrolidinecarboxylic acid, 1-[[1-[[2-[[[3,4-dichlorophenyl]amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]-, phenylmethyl ester, [3R-[3R*[S*(S*)]]]- (9CI)
MF C36 H35 Cl2 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[1(2S)-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-2-[[[3,5-dimethoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
MF C36 H49 N7 O6


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[[(2-bromophenyl)amino]carbonyl]-(2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)

MF C25 H30 Br N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(4-nitrophenyl)amino]carbonyl]propylamino]acetyl]- (9CI)
MF C24 H28 N6 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[3-methyl-2-[[[4-(methylethyl)phenyl]amino]carbonyl]amino]-1-oxobutyl)-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
MF C23 H28 F3 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(cyclohexyl)[[4-ethoxyphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C30 H39 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[1-oxo-3-[(1-phenylethyl)[(3-(trifluoromethyl)phenyl)amino]carbonyl]amino]propyl]- (9CI)
MF C31 H32 F3 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(2,4-difluorophenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI)
MF C26 H31 F2 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Quinoline, 1,2,3,4-tetrahydro-1-[[1-[[[(3-methylphenyl)amino]carbonyl]amino]acetyl]-5-phenyl-2-pyrrolidinyl]carbonyl]-, cis- (9CI)
MF C30 H32 N4 O3


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,5-dichlorophenyl)amino]carbonyl]amino]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C34 H43 Cl2 N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[[(2,6-bis(1-methylethyl)phenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C31 H43 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[[(2,4-dichlorophenyl)amino]carbonyl]propylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C24 H27 Cl2 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[methyl[(3-methylphenyl)amino]carbonyl]amino]acetyl]- (9CI)
MF C23 H27 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[(cyclohexyl)[(4-(methylthio)phenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C29 H37 N5 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(2,4-dichlorophenyl)amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
MF C30 H31 Cl2 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(3-methoxyphenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI)
MF C27 H35 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 4-Thiazolidinecarboxylic acid, 2-(3-pyridinyl)-3-[[[[(3-(trimethylsilyl)ethoxy)carbonyl]phenyl]amino]carbonyl]amino]acetyl]-, 1,1-dimethylethyl ester, (2R-cis)- (9CI)
MF C28 H38 N4 O6 S Si


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(3-chlorophenyl)amino]carbonyl]amino]-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl]- (9CI)
MF C34 H44 Cl N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[4-(1-methylethyl)phenyl]amino]carbonyl] (2-methylpropyl)amino]acetyl]- (9CI)
MF C26 H33 N5 O2


Page 93

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[[3-[(1-methylethyl) [(4-methylphenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C26 H33 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[[3-[[[(3,4-dichlorophenyl)amino]carbonyl]propylamino]-1-oxopropyl]- (9CI)
MF C25 H29 Cl2 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Prolinamide, N-[[[(3-carboxyphenyl)amino]carbonyl]glycyl]-N-(3,4-dimethylbutyl)-5-(2-fluorophenyl)-4-(4-morpholinesulfonyl)-, (2a,4b,5a)- (9CI)
MF C31 H40 F N5 O8 S


JP2004_018717_2.trn

MF C28 H37 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(3-methoxyphenyl)amino]carbonyl]propylamino]acetyl]- (9CI)
MF C25 H31 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[(2-bromophenyl)amino]carbonyl]methylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C22 H24 Br N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[[[3-[(1-methylethyl) [(3-methylphenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C26 H32 N4 O3

Page 94

JP2004_018717_2.trn


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,5-difluorophenyl)amino]carbonyl]amino]-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl]- (9CI)
MF C34 H43 F2 N7 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[4-(4-amino-3,5-dibromophenyl)-1,4-dioxo-2-[[2-pyridinylamino]carbonyl]amino]butyl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI)
 MF C30 H31 Br2 N7 O4



A2003-519222

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[butyl[[3-methylphenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF O26 H33 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]methylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C28 H37 N5 O3

Page 97


JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN D-Proline, N-[[[3-carboxyphenyl]amino]carbonyl]glycyl-5-(2-fluorophenyl)-4-(4-morpholinylcarbonyl)-, 2-(1,1-dimethylethyl) ester, (4S,5S)-rel- (9CI)
 MF C30 H35 F N4 O8


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-2-[[[4-ethoxyphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
 MF C36 H49 N7 O5

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[2,6-dimethylphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C27 H34 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C31 H43 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[1-oxo-3-[propyl[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]propyl]- (9CI)
 MF C26 H30 F3 N5 O2

Page 98


JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-chlorophenyl]amino]carbonyl]amino]-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl]- (9CI)
 MF C34 H44 Cl N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[(3-bromophenyl)amino]carbonyl]butylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C25 H30 Br N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[methyl[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]acetyl]- (9CI)
MF C25 H31 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-(3-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-1-oxopropyl)- (9CI)
MF C26 H29 F3 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-(3-[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl)- (9CI)
MF C30 H32 F6 N4 O3

Page 101

JP2004_018717_2.trn


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[4-phenoxyphenyl]amino]carbonyl]amino]butyl]- (9CI)
MF C40 H49 N7 O5

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[2,4-difluorophenyl]amino]carbonyl]propylamino]-1-oxopropyl)- (9CI)
MF C25 H29 F2 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[4-methylphenyl]amino]carbonyl]amino]-1-oxopropyl)- (9CI)
MF C27 H35 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[4-methylphenyl]amino]carbonyl]amino]-1-oxopropyl)- (9CI)
MF C27 H35 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-bromo-2-methylphenyl]amino]carbonyl]amino]-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
MF C35 H46 Br N7 O4

Page 102


JP2004_018717_2.trn

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[butyl[[[2,4-dimethoxyphenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C27 H35 N5 O5




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[4-(4-chlorophenyl)amino]carbonyl]ethylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C23 H26 Cl N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[2-fluorophenyl]amino]carbonyl]amino]-1-oxopropyl)- (9CI)
MF C26 H31 F N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[cyclohexyl[[[4-ethoxyphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)


MF C30 H38 N4 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-2-[[[4-chlorophenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI)
 MF C24 H28 Cl N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[3-[[butyl[[2,4-dichlorophenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C26 H31 Cl2 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


Page 105

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[ethyl[[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]acetyl]- (9CI)
 MF C24 H26 F3 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[[3-[[butyl[[2-methylphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C27 H34 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[3-[[cyclohexyl[(phenylamino)carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C28 H35 N5 O2


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperazine, 1-[3-methyl-1-oxo-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]butyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
 MF C23 H25 F6 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[2,3-dimethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
 MF C36 H49 N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[butyl[[2-methoxyphenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C26 H33 N5 O4

Page 106


JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-2-[[[4-bromophenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI)
 MF C24 H28 Br N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[[3-[[butyl[[2-methylphenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
 MF C27 H35 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-4-hydroxy-2-[[4-(1-methyl-4-

piperidinyl)-1-piperazinyl]carbonyl]-, (2R,4R)-, (9CI)
MF C22 H32 Cl N5 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2,5-dimethylphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
MF C36 H49 N7 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[(3-chlorophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C25 H30 Cl N5 O3


Page 109



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-3-methyl-2-[[[(4-(1-methylethyl)phenyl)amino]carbonyl]amino]-1-oxobutyl]- (9CI)
MF C27 H35 N5 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[(2-methylpropyl)[[(3-(trifluoromethyl)phenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C27 H32 F3 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3-Pyrrolidinecarboxylic acid, 1-[[1-[(2-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(2,4-dimethoxyphenyl)amino]carbonyl]ethylamino]acetyl]- (9CI)
MF C25 H31 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[2-[[[(4-bromophenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
MF C22 H25 Br F3 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(cyclohexyl)[[(3-fluorophenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C28 H34 F N5 O2

Page 110


yl)carbonyl]-2-pyrrolidinyl]carbonyl]-, (3S-[3R*[R*(S*)]])- (9CI)
MF C29 H29 Cl2 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(4-(1-methylethyl)phenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
MF C37 H51 N7 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(2-fluorophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]- (9CI)
MF C25 H30 F N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[ethyl]([3-methoxyphenyl)amino]carbonyl]amino]acetyl]- (9CI)
MF C24 H29 N5 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[[[2-[[[4-ethylphenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]]- (9CI)
MF C24 H30 F3 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(cyclohexyl[[[2,4-dichlorophenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C28 H33 Cl2 N5 O2

Page 113


JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[[[2S]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[(2,3,4-trifluorophenyl)amino]carbonyl]amino]butyl]]- (9CI)
MF C34 H42 F3 N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[4-chlorophenyl]amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
MF C30 H32 Cl N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[4-bromophenyl]amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI)
MF C26 H32 Br N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 3,4-Pyrrolidinedicarboxylic acid, 1-[[[1-[[[2-[[[3,4-dichlorophenyl]amino]carbonyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]-2-pyrrolidinyl]carbonyl]]- (9CI)
MF C30 H29 Cl2 N5 O7

Page 114


JP2004_018717_2.trn

IN Piperidine, 1-[[[[(4-bromophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C25 H30 Br N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(2-fluorophenyl)amino]carbonyl]propyl]amino]acetyl]- (9CI)
MF C24 H28 F N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[3-methyl-1-oxo-2-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]butyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
MF C23 H25 F6 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[cyclohexyl]([2-methoxyphenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C29 H37 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(2-fluorophenyl)amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
MF C30 H32 F N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(4-ethylphenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI)
MF C28 H37 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN L-Proline, 1-[N-[[[(3-carboxyphenyl)amino]carbonyl]glycyl]-5-(1H-indol-3-yl)-, 2-(1,1-dimethylethyl) ester, cis- (9CI)
MF C27 H30 N4 O6

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(4-ethylphenyl)amino]carbonyl]propylamino]acetyl]- (9CI)
MF C26 H33 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(2-fluorophenyl)amino]carbonyl]methylamino]acetyl]- (9CI)
MF C22 H24 F N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(cyclohexyl)[(4-(trifluoromethyl)phenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C29 H34 F3 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[(2-ethoxyphenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
MF C36 H49 N7 O5

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[[(2,6-dimethylphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]- (9CI)
MF C27 H35 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(4-(1-methylethyl)phenyl)amino]carbonyl](1-phenylethyl)amino]-1-oxopropyl]- (9CI)
MF C33 H39 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(2-methylpropyl)[[(4-(methylthio)phenyl)amino]carbonyl]amino]-1-oxopropyl]- (9CI)
MF C27 H35 N5 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN L-Proline, 5-(1H-indol-3-yl)-1-[N-[[[(3-[[[(2-(trimethylsilyl)ethoxy]carbonyl]phenyl)amino]carbonyl]glycyl]-, 1,1-dimethylethyl ester, trans- (9CI)
MF C32 H42 N4 O6 Si


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[4-(4-fluorophenyl)amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
 MF C34 H44 F N7 O4


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

Page 121




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-bromophenyl]amino]carbonyl]-(1-methylethyl)amino]-1-oxopropyl]- (9CI)
 MF C25 H30 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-methylphenyl]amino]carbonyl]propylamino]-1-oxopropyl]- (9CI)
 MF C26 H33 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Prolinamide, N-[[[3-[(phenylmethoxy)carbonyl]phenyl]amino]carbonyl]glycyl-N-(3,3-dimethylbutyl)-5-(2-fluorophenyl)-4-(4-morpholinesulfonyl)-, (2a,4b,5a)- (9CI)
 MF C38 H46 F N5 O8 S


Relative stereochemistry.

IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[3-methoxyphenyl]amino]carbonyl]-(2-methylpropyl)amino]acetyl]- (9CI)
 MF C26 H33 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[2-methylphenyl]amino]carbonyl]propylamino]acetyl]- (9CI)
 MF C25 H31 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[[4-bromophenyl]amino]carbonyl]methylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C22 H24 Br N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[4-bromophenyl]amino]carbonyl]-(1-methylethyl)amino]-1-oxopropyl]- (9CI)
 MF C25 H29 Br N4 O3


Page 122



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[3-chloro-4-methylphenyl]amino]carbonyl]amino]-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
 MF C35 H46 Cl N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI)
 MF C30 H33 F6 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[butyl[[3-(2,3-dichlorophenyl)amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C25 H30 F2 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[3-[[[2,6-dimethylphenyl]amino]carbonyl]propylamino]-1-oxopropyl]- (9CI)
 MF C24 H29 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

Page 125

JP2004_018717_2.trn

IN Cyclopropanecarboxylic acid, N-[[[2,6-dimethylphenyl]amino]carbonyl]-3-methyl-L-valyl-(4R)-4-[[7-methoxy-2-phenyl-4-quinolinyloxy]-L-prolyl-1-amino-2-ethenyl-, (1R,2S)- (9CI)
 MF C42 H47 N5 O7


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[4-chloro-2-methylphenyl]amino]carbonyl]amino]-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxobutyl]- (9CI)
 MF C35 H46 Cl N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[2-methoxyphenyl]amino]carbonyl] (1-methylethyl)amino]-1-oxopropyl]- (9CI)
 MF C26 H32 N4 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2-benzoxazolyl)-1-[3-[[[3-chlorophenyl]amino]carbonyl]cyclohexylamino]-1-oxopropyl]- (9CI)
 MF C28 H33 Cl N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[3-bromophenyl]amino]carbonyl]propylamino]-1-oxopropyl]- (9CI)
 MF C25 H30 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

Page 126

JP2004_018717_2.trn


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN 1,4'-Bipiperidine, 1'-[(2S)-4-[[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-2-[[[3-ethylphenyl]amino]carbonyl]amino]-1,4-dioxobutyl]- (9CI)
 MF C36 H49 N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 1-[[butyl[[2,3-dichlorophenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
 MF C25 H29 Cl2 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
 IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[3-[[[3-methoxyphenyl]amino]carbonyl]methylamino]acetyl]- (9CI)
 MF C23 H27 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-(3-butyl[(3,4-dichlorophenyl)amino]carbonyl)amino]-1-oxopropyl)- (9CI)
MF C26 H30 Cl2 N4 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-(3-cyclohexyl[(2,3-dichlorophenyl)amino]carbonyl)amino]-1-oxopropyl)- (9CI)
MF C28 H32 Cl2 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-[[[4-ethylphenyl]amino]carbonyl]propylamino]-1-oxopropyl)- (9CI)
MF C27 H35 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-2-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-4-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-1,4-dioxobutyl]- (9CI)
MF C34 H43 Cl2 N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[(butyl[(4-ethoxyphenyl)amino]carbonyl)amino]acetyl]-4-(2,3-



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-(3-[[[(2-bromophenyl)amino]carbonyl]butylamino]-1-oxopropyl)- (9CI)
MF C26 H32 Br N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Benzoic acid, 3-[[[(1S)-1-[(1,4'-bipiperidin)-1'-ylcarbonyl]-3-(4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl)-3-oxopropyl]amino]carbonyl]amino]-, methyl ester (9CI)
MF C36 H47 N7 O6


Absolute stereochemistry.

dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C27 H35 N5 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[ethyl[(4-methylphenyl)amino]carbonyl]amino]acetyl]- (9CI)
MF C24 H29 N5 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-(3-butyl[(2,6-dimethylphenyl)amino]carbonyl)amino]-1-oxopropyl)- (9CI)
MF C28 H36 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(2-benzoxazolyl)-1-(3-cyclohexyl[[[4-(methylthio)phenyl]amino]carbonyl]amino]-1-oxopropyl)- (9CI)
MF C29 H36 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-2-[[[(3-fluorophenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI)
MF C24 H28 F N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(butyl[[[2,6-dimethylphenyl]amino]carbonyl]amino)-1-oxopropyl]- (9CI)
MF C28 H37 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1-Pyrrolidinecarboxamide, N-(4-chlorophenyl)-4-hydroxy-2-[[4-(2-pyridinyl)-


Page 133

JP2004_018717_2.trn




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[[(3-bromophenyl)amino]carbonyl]ethylamino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C23 H26 Br N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperazine, 1-[2-[[[(2-fluorophenyl)amino]carbonyl]amino]-3-methyl-1-oxobutyl]-4-[3-(trifluoromethyl)-2-pyridinyl]- (9CI)
MF C22 H25 F4 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-(cyclohexyl[[[3-methylphenyl]amino]carbonyl]amino)-1-oxopropyl]- (9CI)
MF C29 H37 N5 O2

1-piperazinyl)carbonyl]-, (2R,4R)- (9CI)
MF C21 H24 Cl N5 O3


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 1,4'-Bipiperidine, 1'-[(2S)-4-[4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-1-piperidinyl]-1,4-dioxo-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]aminobutyl]- (9CI)
MF C35 H44 F3 N7 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 1-[[butyl[[[2-methylphenyl]amino]carbonyl]amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI)
MF C26 H33 N5 O3

Page 134


JP2004_018717_2.trn



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[(2S)-2-[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-3-methyl-1-oxobutyl]- (9CI)
MF C30 H41 N5 O2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Piperidine, 4-(1H-benzimidazol-2-yl)-1-[3-[[[(3,4-dichlorophenyl)amino]carbonyl](2-methylpropyl)amino]-1-oxopropyl]- (9CI)
MF C26 H31 Cl2 N5 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 349 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN L-Proline, 1-[1-[N-[(phenylamino)carbonyl]-L-alanyl]-L-prolyl]-, compound with L-arginine (9CI)

MF C20 H26 N4 O5 . x C6 H14 N4 O2


CM 1

Absolute stereochemistry.



A61-53298

Absolute stereochemistry.



ALL ANSWERS HAVE BEEN SCANNED

-> LOG Y
COST IN JAPANESE YEN
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
195	231

STN INTERNATIONAL LOGOFF AT 14:01:27 ON 08 FEB 2005

Host Name: +++
OK
OK

Dialing COMPUSERVE at 0070670488888

OK

CONNECT 46667

Connecting through CompuServe

0029TEA

Host Name: STNT

Connected to 0002 CAA_0

Welcome to STN International! Enter x:x
LOGINID:TKYBAJ74

PASSWORD:

TERMINAL (ENTER 1, 2, 3, EUC, SJIS OR ?):2

***** Welcome to STN International *****

Item	Date	Headline
NEWS 1		STN, CAS FILES Workshop Schedule in Japan
NEWS 2	Oct 26	KOREAPAT now available on STN
NEWS 3	Nov 19	Current-awareness alerts, saved answer sets, and current search transcripts to be affected by CERAB, COMPUAB, ELCOM, and SOLIDSTATE reloads
NEWS 4	Nov 22	November 22, 2004 LISA new on STN
NEWS 5	Dec 1	PHAR reloaded with additional data
NEWS 6	Dec 15	12 databases to be removed from STN on 31.Dec.,2004
NEWS 7	Dec 17	MEDLINE update schedule for December 2004
NEWS 8	Dec 20	ELCOM reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 9	Dec 20	COMPUAB reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 10	Dec 20	SOLIDSTATE reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 11	Dec 20	CERAB reloaded; updating to resume; current-awareness alerts(SDIs) affected
NEWS 12	Dec 20	Three new fields added to IFIPAT/IFIUDB/IFICDB
NEWS 13	Dec 27	EPFULL:New patent full text database to be available on STN
NEWS 14	Dec 31	CAPLUS - PATENT COVERAGE EXPANDED
NEWS 15	Jan 1	No connect-hour charges in EPPULL during January and February 2005
NEWS 16	Jan 5	Urgent announcement to STN customers accessing via phone line WorldCom access points were changed
NEWS 17	Jan 12	CA/CAPLUS - Expanded patent coverage to include the Russian Agency for Patents and Trademarks (ROSPATENT)
NEWS HOURS		STN operating Hours
NEWS WORLDCOM		STN High Speed Access via Worldcom
NEWS INTER		INTERNET ACCESS to STNT(STN-Tokyo)

Page 1

JP2004_018717_4.trn

FILE LAST UPDATED 05 FEBRUARY 2005 (20050205/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow prompt. For the list of suppliers currently in the file, enter HELP SPA, HELP SPBC, HELP SPDH, HELP SPIN, HELP SPOP, and HELP SPOZ. For the list of current catalogs, enter HELP CTA, HELP CTBC, HELP CTDH, HELP CTIN, HELP CTOP, and HELP CTQZ.

This database is provided on an "as is" basis. Please consult the suppliers for current information regarding pricing, regional availability, available quantities, purities, etc. THERE ARE NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. ACS is not liable for any loss of profit, goodwill or any other damages arising out of the use of this database.

CHEMCATS now contains more than 8 million records. See HELP CONTENT and NEWS FILE for details.

=> S L5
L6 256 L5

=> D BIB ABS HITSTR
'BIB' IS NOT A VALID FORMAT FOR FILE 'CHEMCATS'
'ABS' IS NOT A VALID FORMAT FOR FILE 'CHEMCATS'
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'CHEMCATS'
YOU HAVE RECEIVED THIS ERROR MESSAGE 3 CONSECUTIVE TIMES

The following are valid formats:

The default display format is IDE.

ALL ---- AN, CO, PD, ON, CN, RN, ST, Purity, Impurity, product identifiers, product notes, STR, product text (properties, regulatory information, references, prices, warnings, miscellaneous fields), CO, CA, CY, TX (products, terms, and conditions; products and services; packaging and shipping; safety and handling; other supplier information)

COMP ---- AN, CO, PD, CO, TX

IDE ---- AN, CO, PD, ON, CN, RN, LSF, ST, STR

MISC ---- AN, miscellaneous product information fields

PINFO -- AN, pricing information text

PRICE -- AN, prices, quantities

PROD -- AN, product text

PROP -- AN, properties

REF ---- AN, references

REGS ---- AN, regulatory information

SAFE ---- AN, product warnings

SINFO -- AN, safety text

HIT ---- All fields containing hit terms

KWIC ---- All hit terms plus 20 words on either side

OCC ---- List of display fields containing hit terms

Hit terms will be highlighted in all displayable fields.

To display a particular field or fields, enter the display field codes. For a list of display field codes, enter 'HELP DFIELDS' at an arrow prompt (=>). Examples include: 'KWIC'; 'CN RN'; 'IDE CO'. You may specify the formats and fields in any order, and the

NEWS EXPRESS STN Express 7.0 with Discover!
(Windows) Now available!
NEWS WWW STN Tokyo World Wide Web Site

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:45:50 ON 09 FEB 2005

=> FILE REG COS-4PRD
COST IN JAPANESE YEN

SINCE FILE	TOTAL
ENTRY	SESSION
36	36

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:46:06 ON 09 FEB 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)
CHARGED TO COST-4PRD

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0
DICTIONARY FILE UPDATES: 7 FEB 2005 HIGHEST RN 827299-31-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> ACT RD018717A/A
L1 STR
L2 STR
L3 (349)SEA FILE=REGISTRY SSS FUL L1 AND L2
L4 STR
L5 257 SEA FILE=REGISTRY SUB=L3 SSS FUL L4

=> FILE CHEMCATS
COST IN JAPANESE YEN

SINCE FILE	TOTAL
ENTRY	SESSION
65	101

FULL ESTIMATED COST

FILE 'CHEMCATS' ENTERED AT 16:46:27 ON 09 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)
CHARGED TO COST-4PRD

Page 2

JP2004_018717_4.trn

information will be displayed in the same order as the format specification.


The same formats (except for HIT, KWIC, and OCC) may be used with the DISPLAY ACC command to display the record for a specified Accession Number.

IF YOU REQUIRE FURTHER HELP, PLEASE CONTACT YOUR LOCAL HELP DESK
ENTER DISPLAY FORMAT (IDE):END

=> D ALL HITSTR
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'CHEMCATS'
ENTER DISPLAY FORMAT (IDE):END

=> D ALL

L6 ANSWER 1 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2004:1764846 CHEMCATS
Catalog Name (CO): ComGenex Product List
Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0562707
Chemical Name (CN): Piperazine, 1-[3-methyl-1-oxo-2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]butyl]-4-[3-(trifluoromethyl)-2-pyridinyl]-
CAS Registry Number (RN): 684277-53-0
Supplementary Term (ST): CHEMICAL LIBRARY
Structure



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
Princeton Corporate Plaza IV
11 Deer Park Drive, Ste. 210
Monmouth, NJ, 08852
USA


Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: <http://www.comgenex.com>

ComGenex Inc.
Ben rakpart 33/34
Budapest, H-1027
Hungary

Telephone: +36-1-214-2306
 Fax: +36-1-214-2310
 E-mail: info@comgenex.hu

=> D ALL 2-10

L6 ANSWER 2 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
 Accession Number (AN): 2001:903162 CHEMCATS
 Catalog Name (CO): ComGenex Product List
 Publication Date (PD): 26 Jun 2003
 Order Number (ON): CGX-0593617
 Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[2-methylphenyl]amino]carbonyl] (2-methylpropyl)amino]acetyl]-
 CAS Registry Number (RN): 336824-94-3
 Supplementary Term (ST): CHEMICAL LIBRARY
 Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
 Princeton Corporate Plaza IV
 11 Deer Park Drive, Ste. 210
 Monmouth, NJ, 08852
 USA


Telephone: +1-(732) 438-8001
 Fax: +1-(732) 438-8004
 E-mail: info@comgenex.com
 Web: http://www.comgenex.com

ComGenex Inc.
 Bem rakpart 33/34
 Budapest, H-1027
 Hungary

Telephone: +36-1-214-2306
 Fax: +36-1-214-2310
 E-mail: info@comgenex.hu

L6 ANSWER 3 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
 Accession Number (AN): 2001:903161 CHEMCATS
 Catalog Name (CO): ComGenex Product List
 Publication Date (PD): 26 Jun 2003

Page 5



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION


ComGenex International Inc.
 Princeton Corporate Plaza IV
 11 Deer Park Drive, Ste. 210
 Monmouth, NJ, 08852
 USA

Telephone: +1-(732) 438-8001
 Fax: +1-(732) 438-8004
 E-mail: info@comgenex.com
 Web: http://www.comgenex.com

ComGenex Inc.
 Bem rakpart 33/34
 Budapest, H-1027
 Hungary

Telephone: +36-1-214-2306
 Fax: +36-1-214-2310
 E-mail: info@comgenex.hu

L6 ANSWER 5 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
 Accession Number (AN): 2001:903159 CHEMCATS
 Catalog Name (CO): ComGenex Product List
 Publication Date (PD): 26 Jun 2003
 Order Number (ON): CGX-0593613
 Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[4-(1-methylethyl)phenyl]amino]carbonyl] (2-methylpropyl)amino]acetyl]-
 CAS Registry Number (RN): 336824-91-0
 Supplementary Term (ST): CHEMICAL LIBRARY
 Structure :




PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

Order Number (ON): CGX-0593616
 Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[2-methylpropyl]amino]carbonyl] (2-methylthio)phenyl]amino]acetyl]-
 CAS Registry Number (RN): 336824-93-2
 Supplementary Term (ST): CHEMICAL LIBRARY
 Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
 Princeton Corporate Plaza IV
 11 Deer Park Drive, Ste. 210
 Monmouth, NJ, 08852
 USA

Telephone: +1-(732) 438-8001
 Fax: +1-(732) 438-8004
 E-mail: info@comgenex.com
 Web: http://www.comgenex.com

ComGenex Inc.
 Bem rakpart 33/34
 Budapest, H-1027
 Hungary

Telephone: +36-1-214-2306
 Fax: +36-1-214-2310
 E-mail: info@comgenex.hu

L6 ANSWER 4 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
 Accession Number (AN): 2001:903160 CHEMCATS
 Catalog Name (CO): ComGenex Product List
 Publication Date (PD): 26 Jun 2003
 Order Number (ON): CGX-0593614
 Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[3-methoxyphenyl]amino]carbonyl] (2-methylpropyl)amino]acetyl]-
 CAS Registry Number (RN): 336824-92-1
 Supplementary Term (ST): CHEMICAL LIBRARY
 Structure :

Page 6


ComGenex International Inc.
 Princeton Corporate Plaza IV
 11 Deer Park Drive, Ste. 210
 Monmouth, NJ, 08852
 USA

Telephone: +1-(732) 438-8001
 Fax: +1-(732) 438-8004
 E-mail: info@comgenex.com
 Web: http://www.comgenex.com

ComGenex Inc.
 Bem rakpart 33/34
 Budapest, H-1027
 Hungary

Telephone: +36-1-214-2306
 Fax: +36-1-214-2310
 E-mail: info@comgenex.hu

L6 ANSWER 6 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
 Accession Number (AN): 2001:903158 CHEMCATS
 Catalog Name (CO): ComGenex Product List
 Publication Date (PD): 26 Jun 2003
 Order Number (ON): CGX-0593612
 Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[4-(1-methylethyl)phenyl]amino]carbonyl] (2-methylpropyl)amino]acetyl]-
 CAS Registry Number (RN): 336824-90-9
 Supplementary Term (ST): CHEMICAL LIBRARY
 Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION


ComGenex International Inc.
 Princeton Corporate Plaza IV
 11 Deer Park Drive, Ste. 210
 Monmouth, NJ, 08852
 USA

Telephone: +1-(732) 438-8001
 Fax: +1-(732) 438-8004
 E-mail: info@comgenex.com
 Web: http://www.comgenex.com

ComGenex Inc.
Bem rakpart 33/34
Budapest, H-1027
Hungary

Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

L6 ANSWER 7 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903157 CHEMCATS
Catalog Name (CO): ComGenex Product List
Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0593611
Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[4-(4-ethylphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-
CAS Registry Number (RN): 336824-89-6
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION


ComGenex International Inc.
Princeton Corporate Plaza IV
11 Deer Park Drive, Ste. 210
Monmouth, NJ, 08852
USA

Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGenex Inc.
Bem rakpart 33/34
Budapest, H-1027
Hungary

Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

L6 ANSWER 8 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903155 CHEMCATS
Catalog Name (CO): ComGenex Product List



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION


ComGenex International Inc.
Princeton Corporate Plaza IV
11 Deer Park Drive, Ste. 210
Monmouth, NJ, 08852
USA

Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGenex Inc.
Bem rakpart 33/34
Budapest, H-1027
Hungary


Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

L6 ANSWER 10 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903153 CHEMCATS
Catalog Name (CO): ComGenex Product List
Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0593607
Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[2,4-dimethoxyphenyl]amino]carbonyl](2-methylpropyl)amino]acetyl]-
CAS Registry Number (RN): 336824-85-2
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



PRICES

Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0593609
Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[4-(4-ethoxyphenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-
CAS Registry Number (RN): 336824-87-4
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
Princeton Corporate Plaza IV
11 Deer Park Drive, Ste. 210
Monmouth, NJ, 08852
USA

Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGenex Inc.
Bem rakpart 33/34
Budapest, H-1027
Hungary

Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

L6 ANSWER 9 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903154 CHEMCATS
Catalog Name (CO): ComGenex Product List
Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0593608
Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[2,6-dimethylphenyl]amino]carbonyl](2-methylpropyl)amino]acetyl]-
CAS Registry Number (RN): 336824-86-3
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
Princeton Corporate Plaza IV
11 Deer Park Drive, Ste. 210
Monmouth, NJ, 08852
USA


Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGenex Inc.
Bem rakpart 33/34
Budapest, H-1027
Hungary

Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

-> D ALL 11-20

L6 ANSWER 11 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903152 CHEMCATS
Catalog Name (CO): ComGenex Product List
Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0593606
Chemical Name (CN): Piperidine, 1-[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-
CAS Registry Number (RN): 336824-84-1
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
Princeton Corporate Plaza IV
11 Deer Park Drive, Ste. 210
Monmouth, NJ, 08852


USA

Telephone: +1-(732) 438-8001
 Fax: +1-(732) 438-8004
 E-mail: info@comgenex.com
 Web: http://www.comgenex.com

ComGenex Inc.
 Bem rakpart 33/34
 Budapest, H-1027
 Hungary

Telephone: +36-1-214-2306
 Fax: +36-1-214-2310
 E-mail: info@comgenex.hu

L6 ANSWER 12 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
 Accession Number (AN): 2001:903151 CHEMCATS
 Catalog Name (CO): ComGenex Product List
 Publication Date (PD): 26 Jun 2003
 Order Number (ON): CGX-0593604
 Chemical Name (CN): Piperidine, 1-[[[[(2,4-dichlorophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-
 CAS Registry Number (RN): 336824-83-0
 Supplementary Term (ST): CHEMICAL LIBRARY
 Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
 Princeton Corporate Plaza IV
 11 Deer Park Drive, Ste. 210
 Monmouth, NJ, 08852
 USA

Telephone: +1-(732) 438-8001
 Fax: +1-(732) 438-8004
 E-mail: info@comgenex.com
 Web: http://www.comgenex.com


ComGenex Inc.
 Bem rakpart 33/34
 Budapest, H-1027
 Hungary

Telephone: +36-1-214-2306

Page 13

JP2004_018717_4.trn

Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION


ComGenex International Inc.
 Princeton Corporate Plaza IV
 11 Deer Park Drive, Ste. 210
 Monmouth, NJ, 08852
 USA

Telephone: +1-(732) 438-8001
 Fax: +1-(732) 438-8004
 E-mail: info@comgenex.com
 Web: http://www.comgenex.com

ComGenex Inc.
 Bem rakpart 33/34
 Budapest, H-1027
 Hungary

Telephone: +36-1-214-2306
 Fax: +36-1-214-2310
 E-mail: info@comgenex.hu


L6 ANSWER 15 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
 Accession Number (AN): 2001:903148 CHEMCATS
 Catalog Name (CO): ComGenex Product List
 Publication Date (PD): 26 Jun 2003
 Order Number (ON): CGX-0593600
 Chemical Name (CN): Piperidine, 1-[[[[(3-bromophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-
 CAS Registry Number (RN): 336824-80-7
 Supplementary Term (ST): CHEMICAL LIBRARY
 Structure :



PRICES

Fax: +36-1-214-2310
 E-mail: info@comgenex.hu

L6 ANSWER 13 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
 Accession Number (AN): 2001:903150 CHEMCATS
 Catalog Name (CO): ComGenex Product List
 Publication Date (PD): 26 Jun 2003
 Order Number (ON): CGX-0593603
 Chemical Name (CN): Piperidine, 1-[[[[(2,3-dichlorophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-
 CAS Registry Number (RN): 336824-82-9
 Supplementary Term (ST): CHEMICAL LIBRARY
 Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
 Princeton Corporate Plaza IV
 11 Deer Park Drive, Ste. 210
 Monmouth, NJ, 08852
 USA

Telephone: +1-(732) 438-8001
 Fax: +1-(732) 438-8004
 E-mail: info@comgenex.com
 Web: http://www.comgenex.com

ComGenex Inc.
 Bem rakpart 33/34
 Budapest, H-1027
 Hungary

Telephone: +36-1-214-2306
 Fax: +36-1-214-2310
 E-mail: info@comgenex.hu

L6 ANSWER 14 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
 Accession Number (AN): 2001:903149 CHEMCATS
 Catalog Name (CO): ComGenex Product List
 Publication Date (PD): 26 Jun 2003
 Order Number (ON): CGX-0593601
 Chemical Name (CN): Piperidine, 1-[[[[(4-bromophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-
 CAS Registry Number (RN): 336824-81-8
 Supplementary Term (ST): CHEMICAL LIBRARY
 Structure :

Page 14

JP2004_018717_4.trn

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION


ComGenex International Inc.
 Princeton Corporate Plaza IV
 11 Deer Park Drive, Ste. 210
 Monmouth, NJ, 08852
 USA

Telephone: +1-(732) 438-8001
 Fax: +1-(732) 438-8004
 E-mail: info@comgenex.com
 Web: http://www.comgenex.com

ComGenex Inc.
 Bem rakpart 33/34
 Budapest, H-1027
 Hungary

Telephone: +36-1-214-2306
 Fax: +36-1-214-2310
 E-mail: info@comgenex.hu

L6 ANSWER 16 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
 Accession Number (AN): 2001:903147 CHEMCATS
 Catalog Name (CO): ComGenex Product List
 Publication Date (PD): 26 Jun 2003
 Order Number (ON): CGX-0593599
 Chemical Name (CN): Piperidine, 1-[[[[(2-bromophenyl)amino]carbonyl](2-methylpropyl)amino]acetyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-
 CAS Registry Number (RN): 336824-79-4
 Supplementary Term (ST): CHEMICAL LIBRARY
 Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
 Princeton Corporate Plaza IV
 11 Deer Park Drive, Ste. 210
 Monmouth, NJ, 08852
 USA


Telephone: +1-(732) 438-8001

Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGenex Inc.
Bem rakpart 33/34
Budapest, H-1027
Hungary

Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

L6 ANSWER 17 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903144 CHEMCATS
Catalog Name (CO): ComGenex Product List
Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0593594
Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(2-methylpropyl) [[2-(trifluoromethyl)phenyl]amino]carbonyl]amino]acetyl]-
CAS Registry Number (RN): 336824-76-1
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
Princeton Corporate Plaza IV
11 Deer Park Drive, Ste. 210
Monmouth, NJ, 08852
USA


Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGenex Inc.
Bem rakpart 33/34
Budapest, H-1027
Hungary

Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

L6 ANSWER 18 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN

Page 17



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION


ComGenex International Inc.
Princeton Corporate Plaza IV
11 Deer Park Drive, Ste. 210
Monmouth, NJ, 08852
USA

Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGenex Inc.
Bem rakpart 33/34
Budapest, H-1027
Hungary


Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

L6 ANSWER 20 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903141 CHEMCATS
Catalog Name (CO): ComGenex Product List
Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0593591
Chemical Name (CN): Benzoic acid, 4-[[[(2-{4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl}-2-oxoethyl)(2-methylpropyl)amino]carbonyl]amino]-, ethyl ester
CAS Registry Number (RN): 336824-73-8
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



PRICES

Accession Number (AN): 2001:903143 CHEMCATS
Catalog Name (CO): ComGenex Product List
Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0593593
Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(2-fluorophenyl)amino]carbonyl] (2-methylpropyl)amino]acetyl]-
CAS Registry Number (RN): 336824-75-0
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
Princeton Corporate Plaza IV
11 Deer Park Drive, Ste. 210
Monmouth, NJ, 08852
USA

Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGenex Inc.
Bem rakpart 33/34
Budapest, H-1027
Hungary

Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

L6 ANSWER 19 OF 256 CHEMCATS COPYRIGHT 2005 ACS on STN
Accession Number (AN): 2001:903142 CHEMCATS
Catalog Name (CO): ComGenex Product List
Publication Date (PD): 26 Jun 2003
Order Number (ON): CGX-0593592
Chemical Name (CN): Piperidine, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-[[[(2-fluorophenyl)amino]carbonyl] (2-methylpropyl)amino]acetyl]-
CAS Registry Number (RN): 336824-74-9
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :

Page 18

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

ComGenex International Inc.
Princeton Corporate Plaza IV
11 Deer Park Drive, Ste. 210
Monmouth, NJ, 08852
USA

Telephone: +1-(732) 438-8001
Fax: +1-(732) 438-8004
E-mail: info@comgenex.com
Web: http://www.comgenex.com

ComGenex Inc.
Bem rakpart 33/34
Budapest, H-1027
Hungary

Telephone: +36-1-214-2306
Fax: +36-1-214-2310
E-mail: info@comgenex.hu

> LOG Y

COST IN JAPANESE YEN

SINCE FILE	TOTAL
ENTRY	SESSION
10461	10562

FULL ESTIMATED COST

STN INTERNATIONAL LOGOFF AT 16:50:28 ON 09 FEB 2005

Host Name: +++

OK

OK

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.